[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2303
1. Tadjine M, Lampron A, Ouadi L, Bourdeau I: Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf); 2008 Feb;68(2):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our previous work, we demonstrated the differential expression of several Wnt/beta-catenin signalling-related genes implicated in ACTH-independent macronodular adrenal hyperplasias (AIMAH).
  • METHODS: We studied 53 human adrenocortical samples (33 adenomas, 4 carcinomas, 13 AIMAH, 3 ACTH-dependent adrenal hyperplasias) and the human adrenocortical cancer cell line NCI-H295R.
  • CONCLUSIONS: Activating mutations of exon 3 of the beta-catenin gene are frequent in adrenocortical adenomas, and further characterization of the Wnt/beta-catenin signalling pathway should lead to a better understanding of adrenal tumourigenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854394.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin
  •  go-up   go-down


2. Wedmid A, Palese M: Diagnosis and treatment of the adrenal cyst. Curr Urol Rep; 2010 Feb;11(1):44-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of the adrenal cyst.
  • Adrenal cysts, first described in 1670, typically presented with abdominal pain or palpable mass.
  • In the modern era, incidentally identified adrenal cysts are commonplace, as imaging studies have become a mainstay in patient evaluation.
  • The rubric of adrenal cysts comprises a broad differential diagnosis, rendering definitive diagnosis and subsequent management difficult.
  • Radiologic differentiation is helpful; however, imaging characteristics, such as hemorrhage in a pseudocyst, can confound identification of benign versus malignant lesions.
  • Any functional lesion, potentially malignant lesion, or benign lesion more than 5 cm in diameter deserves surgical treatment.
  • [MeSH-major] Adrenal Gland Diseases. Adrenalectomy / methods. Cysts. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):915-7 [15711326.001]
  • [Cites] Hum Pathol. 1989 May;20(5):491-2 [2707800.001]
  • [Cites] Med Princ Pract. 2008;17(5):419-21 [18685285.001]
  • [Cites] Endocr Pract. 2008 Apr;14(3):269-78 [18463032.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1817-20 [16983481.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):660-5 [2737661.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):34-40 [19125016.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1537-44 [15378490.001]
  • [Cites] Radiographics. 2004 Oct;24 Suppl 1:S73-86 [15486251.001]
  • [Cites] J Endocrinol Invest. 1998 Feb;21(2):109-14 [9585385.001]
  • [Cites] Int Braz J Urol. 2004 Jan-Feb;30(1):35-6 [15707514.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):95-112 [11809539.001]
  • [Cites] Eur J Radiol. 2006 Dec;60(3):465-9 [16962278.001]
  • [Cites] BJU Int. 2008 Feb;101(3):345-50 [18070168.001]
  • [Cites] Endocr Pathol. 2008 Winter;19(4):274-81 [18972224.001]
  • [Cites] Endocr Pathol. 2008 Fall;19(3):203-5 [18446449.001]
  • [Cites] J Urol. 1959 Jun;81(6):711-9 [13655392.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):34-46 [18043254.001]
  • [Cites] Arch Surg. 1966 Jan;92(1):131-43 [5901251.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):531-5 [12594556.001]
  • [Cites] J Am Coll Surg. 2008 May;206(5):953-9; discussion 959-61 [18471733.001]
  • [Cites] Int Urol Nephrol. 2005;37(4):767-71 [16362596.001]
  • [Cites] AJR Am J Roentgenol. 2008 May;190(5):1163-8 [18430826.001]
  • [Cites] BJU Int. 2009 Sep;104(6):847-50 [19389014.001]
  • [Cites] Am Surg. 2005 Apr;71(4):321-5 [15943406.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):583-7 [14713764.001]
  • [Cites] Am Surg. 2003 Sep;69(9):812-4 [14509334.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):67-72 [18366977.001]
  • [Cites] Am Surg. 1997 Aug;63(8):744-6 [9247446.001]
  • [Cites] Am Surg. 1999 Feb;65(2):151-63 [9926751.001]
  • [Cites] Eur J Radiol. 2007 Jun;62(3):359-70 [17532488.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):220 [11285972.001]
  • (PMID = 20425637.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


3. Pushkarev VM, Tronko ND, Kostyuchenko NN, Mikosha AS: Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukr Biokhim Zh (1999); 2007 Mar-Apr;79(2):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex.
  • The actions of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD), potassium and lithium ions upon apoptotic processes in conventionally normal and tumour tissues of human adrenal cortex were studied.
  • There was no effect of K+ on the apoptosis in tumour tissue. o,p'-DDD--the specific drug for conservative therapy of adrenocortical cancer--enhanced the apoptotic DNA fragmentation in all tested tissues.
  • The conclusion was made that apoptosis may be involved in curative effect of o,p'-DDD in adrenal cortex.
  • On the other hand, lithium enhanced the DNA fragmentation in the postoperative tissue of patients with Cushing disease.
  • The possible mechanisms mediating lithium effects on the adrenal cortex are discussed.
  • [MeSH-major] Adrenal Cortex / drug effects. Adrenal Cortex Neoplasms / pathology. Antineoplastic Agents, Hormonal / pharmacology. Apoptosis / drug effects. DNA Fragmentation / drug effects. Lithium Chloride / pharmacology. Mitotane / pharmacology
  • [MeSH-minor] Humans. Potassium Chloride / pharmacology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. MITOTANE .
  • Hazardous Substances Data Bank. POTASSIUM CHLORIDE .
  • Hazardous Substances Data Bank. LITHIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030749.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 660YQ98I10 / Potassium Chloride; 78E4J5IB5J / Mitotane; G4962QA067 / Lithium Chloride
  •  go-up   go-down


Advertisement
4. Bauditz J, Quinkler M, Beyersdorff D, Wermke W: Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound. Oncol Rep; 2008 May;19(5):1135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound.
  • Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy whose pathogenesis and poor prognosis is poorly understood.
  • Computerized tomography (CT) and magnetic resonance imaging (MRI) are routinely performed for the imaging of the adrenal mass and for standard staging of the chest and abdomen as the lung and liver are the primary organs for metastasis in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Contrast Media / pharmacology. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425368.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Martarelli D, Pompei P, Baldi C, Mazzoni G: Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol; 2008 Apr;61(5):809-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical carcinoma is a rare tumor of the adrenal gland which requires new therapeutic approaches as its early diagnosis is difficult and prognosis poor despite therapies used.
  • Recently, mebendazole has been proved to be effective against different cancers.
  • Mebendazole significantly inhibited cancer cells growth, both in vitro and in vivo, the effects being due to the induction of apoptosis.
  • Moreover, mebendazole inhibited invasion and migration of cancer cells in vitro, and metastases formation in vivo.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Humans. In Vitro Techniques. Male. Mice. Mice, Nude. Neoplasm Metastasis / prevention & control. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MEBENDAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581752.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 81G6I5V05I / Mebendazole
  •  go-up   go-down


6. Crivellato E, Finato N, Ribatti D, Beltrami CA: Piecemeal degranulation in human tumour pheochromocytes. J Anat; 2005 Jan;206(1):47-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piecemeal degranulation in human tumour pheochromocytes.
  • Piecemeal degranulation (PMD) has been recognized in two cases of human pheochromocytoma from the adrenal medulla, which were studied by transmission electron microscopy.
  • Tumour pheochromocytes presented a highly characteristic cytoplasmic admixture of normal resting granules, swollen granules with eroded matrices and enlarged empty containers.
  • This is the first description of PMD in human adrenal chromaffin cells and, in addition, is the first report of PMD in tumour secretory cells.
  • [MeSH-major] Adrenal Gland Neoplasms / secretion. Cell Degranulation. Pheochromocytoma / secretion

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):557-62 [1755112.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1990;93(2-3):113-9 [2099339.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4090-101 [8943842.001]
  • [Cites] Cell Tissue Res. 1998 Jul;293(1):1-22 [9634593.001]
  • [Cites] J Allergy Clin Immunol. 1998 Aug;102(2):286-94 [9723674.001]
  • [Cites] J Anat. 1965 Apr;99:231-54 [14330730.001]
  • [Cites] Am J Surg Pathol. 1983 Jan;7(1):29-37 [6338750.001]
  • [Cites] Regul Pept. 1986 Jan;13(2):169-82 [3513267.001]
  • [Cites] Am J Anat. 1987 Jan;178(1):85-9 [3825966.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Oct;23(4):521-9 [11017918.001]
  • [Cites] Anat Rec. 2002 Dec 1;268(4):353-9 [12420282.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Feb;270(2):103-8 [12524685.001]
  • [Cites] Hypertens Res. 2003 Feb;26 Suppl:S71-8 [12630814.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Sep;274(1):778-84 [12923888.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Mar;277(1):204-8 [14983514.001]
  • [Cites] Clin Chim Acta. 2004 Jul;345(1-2):43-7 [15193976.001]
  • [Cites] Pathol Annu. 1970;5:145-71 [4939997.001]
  • [Cites] J Exp Med. 1973 Mar 1;137(3):751-75 [4347597.001]
  • [Cites] Lab Invest. 1974 Aug;31(2):111-30 [4604792.001]
  • [Cites] J Immunol. 1976 Mar;116(3):687-95 [1254949.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Mar;56(3):582-5 [6822655.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):1996-2004 [2450643.001]
  • [Cites] Neuroscience. 1988 May;25(2):679-86 [3399061.001]
  • [Cites] J Electron Microsc Tech. 1989 Aug;12(4):316-22 [2769434.001]
  • [Cites] J Electron Microsc Tech. 1989 Aug;12(4):364-79 [2671305.001]
  • [Cites] Cell Tissue Res. 1990 Dec;262(3):415-24 [1706643.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):795-807 [1562046.001]
  • (PMID = 15679870.001).
  • [ISSN] 0021-8782
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1571454
  •  go-up   go-down


7. Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K: Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf; 2007;30(11):1031-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Problems arise most often when drugs or therapeutic procedures are employed in patients in whom the tumour is not suspected.
  • In such cases, it is extremely important for the clinician to recognise the possibility of an underlying catecholamine-producing tumour and to take the most appropriate steps to manage and treat adverse events and clinical complications.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Catecholamines / physiology. Drug-Related Side Effects and Adverse Reactions. Pheochromocytoma / complications

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1833-8 [11117974.001]
  • [Cites] Br Heart J. 1990 Apr;63(4):234-7 [2337495.001]
  • [Cites] Lancet. 1984 Aug 11;2(8398):355 [6146900.001]
  • [Cites] AJR Am J Roentgenol. 2007 Apr;188(4):970-4 [17377032.001]
  • [Cites] Ital Heart J. 2002 Jun;3(6):375-8 [12116803.001]
  • [Cites] Anesthesiology. 1979 Apr;50(4):366-9 [434546.001]
  • [Cites] Circulation. 1996 May 1;93(9):1667-76 [8653872.001]
  • [Cites] Cell Tissue Res. 2005 Dec;322(3):443-53 [16047163.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1999-2008 [11344198.001]
  • [Cites] Chin Med J (Engl). 1998 Nov;111(11):1018-24 [11189207.001]
  • [Cites] Hypertens Res. 2004 Mar;27(3):193-202 [15080378.001]
  • [Cites] Medicine (Baltimore). 1968 Sep;47(5):371-409 [4386574.001]
  • [Cites] Br J Clin Pharmacol. 1979 Apr;8 Suppl 2:229S-32S [26635172.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4460-7 [11549694.001]
  • [Cites] Nephrol Dial Transplant. 2001 Oct;16(10):2092-4 [11572905.001]
  • [Cites] Cancer. 1978 Oct;42(4):2005-8 [361218.001]
  • [Cites] J Hypertens. 1984 Apr;2(2):127-9 [6533183.001]
  • [Cites] Ann Intern Med. 1997 Feb 15;126(4):333 [9036813.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):425-30 [1732769.001]
  • [Cites] Johns Hopkins Med J. 1976 Sep;139(3):137-44 [972439.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2068-75 [15644397.001]
  • [Cites] Aust N Z J Med. 2000 Dec;30(6):648-52 [11198571.001]
  • [Cites] Ann Fr Anesth Reanim. 1987;6(3):204-6 [3619154.001]
  • [Cites] BMJ. 2001 May 19;322(7296):1213 [11358774.001]
  • [Cites] Nephrol Dial Transplant. 2001 Oct;16(10):2100-4 [11572908.001]
  • [Cites] Anesthesiology. 2004 Oct;101(4):1022-4 [15448539.001]
  • [Cites] Pediatr Neurosurg. 2002 Jan;36(1):48-51 [11818748.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Aug;65(2):186-90 [16886958.001]
  • [Cites] Anesthesiology. 1986 Nov;65(5):474-9 [3777477.001]
  • [Cites] Arch Intern Med. 1999 Nov 22;159(21):2601-3 [10573053.001]
  • [Cites] Scott Med J. 2001 Feb;46(1):14-5 [11310355.001]
  • [Cites] Endocrinol Metab Clin North Am. 2006 Dec;35(4):699-724, viii [17127142.001]
  • [Cites] Lancet. 1974 Sep 28;2(7883):782 [4143044.001]
  • [Cites] Am J Surg. 2000 Mar;179(3):212-5 [10827323.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1037-42 [12192533.001]
  • [Cites] Radiology. 1972 Mar;102(3):579-80 [5060162.001]
  • [Cites] Crit Care Med. 1992 Apr;20(4):549-51 [1559374.001]
  • [Cites] Br Med J. 1980 Aug 2;281(6236):387 [7427286.001]
  • [Cites] J Reprod Med. 1983 Feb;28(2):159-62 [6834356.001]
  • [Cites] Ann Intern Med. 1967 Jun;66(6):1091-6 [6027944.001]
  • [Cites] Am J Surg. 1967 Dec;114(6):927-31 [6060771.001]
  • [Cites] Clin Exp Hypertens A. 1992;14(1-2):251-60 [1541039.001]
  • [Cites] Am Heart J. 1980 Nov;100(5):716-22 [7446367.001]
  • [Cites] Ann Surg Oncol. 2006 Dec;13(12):1696-701 [17009139.001]
  • [Cites] Schweiz Med Wochenschr. 1960 Jan 9;90:31-9 [13856332.001]
  • [Cites] Acta Anaesthesiol Scand. 2004 Jul;48(6):711-5 [15196103.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):759-63; discussion 763-4 [1413846.001]
  • [Cites] Thorac Cardiovasc Surg. 2006 Oct;54(7):498-9 [17089320.001]
  • [Cites] Endocr Pract. 2000 May-Jun;6(3):249-52 [11421540.001]
  • [Cites] JAMA. 1991 Sep 18;266(11):1553-5 [1880888.001]
  • [Cites] Physiol Rev. 1995 Apr;75(2):369-92 [7724667.001]
  • [Cites] Can J Cardiol. 2003 Apr;19(5):573-6 [12717495.001]
  • [Cites] Br Med J. 1974 Jun 8;2(5918):538 [4135015.001]
  • [Cites] Postgrad Med J. 1967 Mar;43(497):180-3 [6037731.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1992 May;19(5):287-90 [1521358.001]
  • [Cites] Arch Intern Med. 1993 Sep 13;153(17):2061 [8357292.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] Anaesthesist. 1985 Aug;34(8):392-5 [4051167.001]
  • [Cites] Eur J Emerg Med. 2004 Aug;11(4):237-9 [15249816.001]
  • [Cites] Arch Mal Coeur Vaiss. 1990 Jul;83(8):1123-5 [2124450.001]
  • [Cites] J Am Med Assoc. 1959 Apr 11;169(15):1749-52 [13640932.001]
  • [Cites] Jpn Circ J. 2000 Oct;64(10):785-8 [11059621.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):317-24 [2195784.001]
  • [Cites] Lancet. 1978 May 13;1(8072):1045-6 [76965.001]
  • [Cites] Clin Infect Dis. 2006 Jun 1;42(11):1578-83 [16652315.001]
  • [Cites] Surgery. 1986 Dec;100(6):1154-62 [3787474.001]
  • [Cites] J Cardiovasc Pharmacol. 1993 Jul;22(1):22-6 [7690091.001]
  • [Cites] Intern Med. 2001 Jul;40(7):638-42 [11506307.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):752-7 [496116.001]
  • [Cites] JAMA. 1974 Sep 2;229(10):1282 [4212135.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):3968-72 [11095415.001]
  • [Cites] Clin Nephrol. 1985 Jul;24(1):47-9 [4017298.001]
  • [Cites] Urology. 2006 Apr;67(4):846.e19-20 [16600345.001]
  • [Cites] Am J Surg. 1960 Apr;99:458-96 [13852560.001]
  • [Cites] N Engl J Med. 1987 Mar 26;316(13):793-7 [2881206.001]
  • [Cites] Aust N Z J Med. 1987 Apr;17(2):246-8 [3476062.001]
  • [Cites] JAMA. 1971 Feb 22;215(8):1323-4 [5107568.001]
  • [Cites] Am J Hypertens. 1996 Aug;9(8):760-9 [8862222.001]
  • [Cites] Am J Nephrol. 1997;17(5):474-6 [9382171.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):193-9 [8717160.001]
  • [Cites] J Endocrinol Invest. 2002 Jun;25(6):567-71 [12109632.001]
  • [Cites] Anesthesiology. 1981 Aug;55(2):180-3 [6455073.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):563-9 [15509646.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102 [17237836.001]
  • [Cites] Eur J Med Res. 1998 Dec 16;3(12):549-53 [9889174.001]
  • [Cites] Int Arch Allergy Immunol. 1996 May;110(1):13-22 [8645973.001]
  • [Cites] J Neurochem. 2006 Sep;98(6):1828-40 [16945103.001]
  • [Cites] Surgery. 1988 Dec;104(6):1064-73 [3194833.001]
  • [Cites] BMJ. 1994 Oct 8;309(6959):958 [7950687.001]
  • [Cites] Pharmacol Ther. 2001 Jul;91(1):35-62 [11707293.001]
  • [Cites] Anaesth Intensive Care. 1999 Dec;27(6):646-9 [10631422.001]
  • [Cites] Cardiol Rev. 2005 Mar-Apr;13(2):69-72 [15705255.001]
  • [Cites] South Med J. 1980 Jun;73(6):795-6 [6104859.001]
  • [Cites] Eur Urol. 2004 Feb;45(2):226-32 [14734011.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1018:224-30 [15240373.001]
  • [Cites] Ann Nucl Med. 1994 May;8(2):133-7 [7521194.001]
  • [Cites] Ann Surg. 1990 Nov;212(5):621-8 [1978640.001]
  • [Cites] Br Med J. 1977 Jan 8;1(6053):84 [832022.001]
  • [Cites] N Engl J Med. 2000 Aug 3;343(5):352-6 [10922426.001]
  • [Cites] Anesth Analg. 1977 Sep-Oct;56(5):729-31 [562104.001]
  • [Cites] South Med J. 1977 Nov;70(11):1320-1 [918700.001]
  • [Cites] DICP. 1991 Oct;25(10):1068-70 [1725079.001]
  • [Cites] Anaesthesia. 1978 May;33(5):473-7 [352186.001]
  • [Cites] J Hypertens. 1994 May;12(5):609-15 [7930562.001]
  • [Cites] Radiology. 1981 Sep;140(3):841-5 [7280260.001]
  • [Cites] Int J Clin Pract. 2003 Jul-Aug;57(6):547-8 [12918898.001]
  • [Cites] Am J Emerg Med. 2001 Mar;19(2):130-3 [11239257.001]
  • [Cites] Br J Radiol. 2006 May;79(941):368-71 [16632615.001]
  • [Cites] N Engl J Med. 1977 Jan 6;296(1):50-1 [830274.001]
  • [Cites] Anaesth Intensive Care. 2002 Aug;30(4):477-80 [12180588.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):56-61 [8027253.001]
  • [Cites] Hypertension. 1990 Feb;15(2 Suppl):I59-62 [1967592.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Jan;42(1):95-8; discussion 98-9 [7889639.001]
  • [Cites] Am J Emerg Med. 1994 Mar;12(2):190-2 [8161395.001]
  • [Cites] Lancet. 1962 Jul 21;2(7247):126-8 [14490201.001]
  • [Cites] Eur J Med. 1993 Oct-Nov;2(8):506-8 [8258057.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):494-5 [475193.001]
  • [Cites] AJR Am J Roentgenol. 1976 Mar;126(3):567-75 [178204.001]
  • [Cites] J Cardiovasc Surg (Torino). 1989 Mar-Apr;30(2):284-7 [2651458.001]
  • [Cites] Fed Proc. 1980 Apr;39(5):1575-9 [7364054.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(3):283-5 [3153240.001]
  • [Cites] Anesth Analg. 2000 Nov;91(5):1118-23 [11049893.001]
  • [Cites] Pflugers Arch. 2000 Jun;440(2):253-63 [10898526.001]
  • [Cites] J Clin Anesth. 1999 May;11(3):247-50 [10434223.001]
  • [Cites] Ann Intern Med. 1964 Nov;61:924-7 [14233813.001]
  • [Cites] Am J Obstet Gynecol. 1988 May;158(5):1107-15 [2967034.001]
  • [Cites] Anesth Analg. 1987 Aug;66(8):723-30 [2440351.001]
  • [Cites] Klin Wochenschr. 1982 Nov 15;60(22):1393-400 [7176461.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2006 Jun;20(3):394-6 [16750744.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Nov;59(2):133-7 [9431876.001]
  • [Cites] J Biol Chem. 1985 Apr 10;260(7):4409-17 [3980483.001]
  • [Cites] Lancet. 1983 Sep 24;2(8352):711-3 [6136843.001]
  • [Cites] Singapore Med J. 2005 Oct;46(10):557-60 [16172777.001]
  • [Cites] Ann Pharmacother. 2005 May;39(5):970-2 [15811908.001]
  • [Cites] Postgrad Med J. 1982 Aug;58(682):503-6 [7134092.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:1-10 [12381537.001]
  • [Cites] Anesth Analg. 1998 Aug;87(2):434-8 [9706946.001]
  • [Cites] Br J Anaesth. 1995 Nov;75(5):588-92 [7577286.001]
  • [Cites] Ann Acad Med Singapore. 1998 Nov;27(6):843-8 [10101561.001]
  • [Cites] J Clin Psychopharmacol. 1997 Oct;17(5):428-30 [9315999.001]
  • [Cites] Br Heart J. 1979 Sep;42(3):359-61 [508460.001]
  • [Cites] Ann Surg. 1983 Apr;197(4):484-90 [6830355.001]
  • [Cites] Intern Med J. 2006 Sep;36(9):604-6 [16911553.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Feb;54(2):447-9 [7033279.001]
  • [Cites] Arch Surg. 1987 Jul;122(7):833-4 [3592975.001]
  • [Cites] Postgrad Med J. 1995 Jan;71(831):58-9 [7708599.001]
  • [Cites] Postgrad Med J. 2000 May;76(895):303 [10775287.001]
  • [Cites] Am J Med Sci. 1974 Jun;267(6):337-43 [4841904.001]
  • [Cites] Anaesthesist. 1986 Oct;35(10):628-33 [3789391.001]
  • [Cites] Neurochem Res. 1993 Nov;18(11):1145-9 [8255365.001]
  • [Cites] Can J Anaesth. 2002 Feb;49(2):148-50 [11823392.001]
  • [Cites] Br Med J. 1978 May 27;1(6124):1395-6 [647306.001]
  • [Cites] Masui. 2004 Dec;53(12):1391-5 [15682801.001]
  • [Cites] Neurosci Lett. 1991 Jan 28;122(2):261-4 [1827517.001]
  • [Cites] Anaesthesia. 2001 Oct;56(10):1015-6 [11576126.001]
  • [Cites] Ophthalmic Surg. 1989 Sep;20(9):647-9, Discussion, 650 [2812693.001]
  • [Cites] Anesthesiology. 1978 Nov;49(5):368-9 [736292.001]
  • [Cites] Masui. 2002 May;51(5):516-7 [12058437.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1852-6 [7989494.001]
  • [Cites] Anasth Intensivther Notfallmed. 1988 Apr;23(2):77-81 [3394904.001]
  • [Cites] Drug Saf. 1991 Jan-Feb;6(1):28-36 [2029351.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2001 Aug 10;90(8):1522-4 [11573274.001]
  • [Cites] Anesth Analg. 1987 Apr;66(4):314-6 [3565793.001]
  • [Cites] Anesth Analg. 2004 Sep;99(3):680-6, table of contents [15333393.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):2195-203 [10372731.001]
  • [Cites] Lancet. 1963 Oct 26;2(7313):849-50 [14056007.001]
  • [Cites] Br J Dermatol. 1987 Sep;117(3):371-6 [3676085.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1739-41 [6896844.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Nervenarzt. 1998 Jan;69(1):76-7 [9522337.001]
  • [Cites] J Neurosurg Anesthesiol. 1989 Mar;1(1):68-72 [15815242.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):31-4 [15615946.001]
  • [Cites] Br J Anaesth. 1986 Dec;58(12):1453-68 [3539166.001]
  • [Cites] J Endocrinol Invest. 1990 Nov;13(10):807-15 [2096157.001]
  • [Cites] Acta Anaesthesiol Sin. 1998 Sep;36(3):169-72 [9874867.001]
  • [Cites] Clin Med Res. 2004 Feb;2(1):59-62 [15931336.001]
  • [Cites] Drugs. 1998 Nov;56(5):929-55 [9829161.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:449-64 [17102114.001]
  • [Cites] Clin Pharmacol Ther. 1995 Jul;58(1):81-9 [7543038.001]
  • [Cites] J Am Soc Echocardiogr. 2006 Dec;19(12 ):1466-70 [17138031.001]
  • [Cites] Anesthesiology. 1977 May;46(5):359-61 [851247.001]
  • [Cites] Jpn Heart J. 1985 Jul;26(4):557-66 [4057555.001]
  • [Cites] Acta Med Scand. 1962 Nov;172:525-9 [13931669.001]
  • [Cites] Ann Fr Anesth Reanim. 1996;15(2):142-8 [8734233.001]
  • [Cites] Radiology. 1997 Jan;202(1):227-31 [8988215.001]
  • [Cites] Anesthesiology. 1995 Apr;82(4):919-25 [7717564.001]
  • [Cites] Hypertension. 1986 Sep;8(9):810-2 [3744472.001]
  • [Cites] Pediatr Emerg Care. 2003 Jun;19(3):174-7 [12813305.001]
  • [Cites] Anesth Analg. 1995 Jul;81(1):152-62 [7598246.001]
  • [Cites] AJR Am J Roentgenol. 1984 Jul;143(1):43-6 [6610328.001]
  • [Cites] J Neurosci. 1998 Aug 1;18(15):5575-85 [9671649.001]
  • [Cites] J Endocrinol Invest. 2006 Jul-Aug;29(7):650-2 [16957415.001]
  • [Cites] Clin Pharmacol Ther. 1982 Aug;32(2):156-60 [7094503.001]
  • [Cites] Am J Emerg Med. 1989 Jan;7(1):44-8 [2643960.001]
  • [Cites] Am J Hypertens. 1990 Jun;3(6 Pt 2):22S-24S [2143384.001]
  • [Cites] JAMA. 1968 Aug 19;205(8):547-53 [5694996.001]
  • [Cites] Arch Neurol. 1976 Apr;33(4):281-8 [1259642.001]
  • [Cites] Pol Merkur Lekarski. 2003 Jul;15(85):95-7 [14593970.001]
  • [Cites] Peptides. 2001 Apr;22(4):597-600 [11311729.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):217-8 [10206419.001]
  • [Cites] Rev Clin Esp. 1979 Feb 28;152(4):327-9 [451312.001]
  • [Cites] Acta Physiol Scand. 1999 Oct;167(2):89-97 [10571543.001]
  • [Cites] J Neurosurg Anesthesiol. 2004 Jan;16(1):26-8 [14676566.001]
  • [Cites] Int Anesthesiol Clin. 1998 Summer;36(3):31-44 [10812414.001]
  • [Cites] AJR Am J Roentgenol. 1986 Apr;146(4):741-4 [3485346.001]
  • [Cites] J Neurosci. 1983 Apr;3(4):871-6 [6834109.001]
  • [Cites] Pharmacol Ther. 2003 Apr;98(1):1-34 [12667886.001]
  • [Cites] South Med J. 2004 Oct;97(10):981-4 [15558925.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:405-16 [17102109.001]
  • [Cites] Nihon Naibunpi Gakkai Zasshi. 1991 Jan 20;67(1):1-7 [2013344.001]
  • [Cites] Aust N Z J Med. 1995 Jun;25(3):257 [7487700.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] JAMA. 1968 Sep 23;205(13):895-9 [5695396.001]
  • [Cites] Int J Cardiol. 1993 Nov;42(1):79-86 [8112909.001]
  • [Cites] Prog Neurobiol. 2005 Apr;75(6):406-33 [15955613.001]
  • [Cites] Lancet. 1977 Mar 12;1(8011):600 [65683.001]
  • [Cites] Acta Anaesthesiol Sin. 1999 Mar;37(1):27-8 [10407524.001]
  • [Cites] Mayo Clin Proc. 1981 Jun;56(6):354-60 [6453259.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:1-20 [17102067.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Mar;24(3):319-25 [3708878.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 Nov-Dec;15(9):1563-7 [12503867.001]
  • [Cites] G Ital Cardiol. 1992 Nov;22(11):1327-30 [1297619.001]
  • [Cites] Hypertension. 1990 Feb;15(2 Suppl):I128-31 [2298468.001]
  • [Cites] Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):809-15 [990158.001]
  • [Cites] Am J Med. 1980 Aug;69(2):321-4 [6105823.001]
  • [Cites] Ann Intern Med. 2004 May 18;140(10):849-51 [15148085.001]
  • [Cites] Dtsch Med Wochenschr. 1996 Apr 12;121(15):479-84 [8605840.001]
  • [Cites] Am J Med Sci. 1997 Dec;314(6):396-8 [9413344.001]
  • [Cites] Endocr J. 2005 Apr;52(2):193-8 [15863947.001]
  • [Cites] J Clin Invest. 1964 Jan;43:94-102 [14105236.001]
  • [Cites] Clin Pharmacol Ther. 1985 Apr;37(4):372-5 [3978997.001]
  • [Cites] Lancet. 1976 Dec 18;2(7999):1357-8 [63830.001]
  • [Cites] Annu Rev Neurosci. 2004;27:509-47 [15217342.001]
  • [Cites] Am J Kidney Dis. 2002 Jun;39(6):E23 [12046054.001]
  • [Cites] Nephrol Dial Transplant. 2001 May;16(5):1069-72 [11328920.001]
  • [Cites] Hypertension. 2004 May;43(5):907-10 [15023935.001]
  • [Cites] Med Pediatr Oncol. 1994;22(6):389-92 [8152400.001]
  • [Cites] Acta Med Scand. 1986;220(3):225-32 [3776697.001]
  • [Cites] Res Vet Sci. 1996 Mar;60(2):134-7 [8685534.001]
  • [Cites] Diabetes Care. 1992 Oct;15(10):1437-8 [1425117.001]
  • [Cites] Br J Anaesth. 2000 Jul;85(1):44-57 [10927994.001]
  • [Cites] Anaesth Intensive Care. 2005 Aug;33(4):525-7 [16119498.001]
  • [Cites] N Engl J Med. 1976 Sep 9;295(11):605-7 [820996.001]
  • [Cites] Br J Anaesth. 2004 Apr;92(4):512-7 [14766711.001]
  • [Cites] JAMA. 1966 Jun 27;196(13):1107-13 [5952510.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):239-48 [12872341.001]
  • [Cites] Med Princ Pract. 2006;15(5):358-61 [16888393.001]
  • [Cites] J Endocrinol Invest. 1997 Feb;20(2):65-71 [9125485.001]
  • [Cites] J Am Med Assoc. 1955 Apr 16;157(16):1404-6 [14366991.001]
  • [Cites] Arch Surg. 1988 Aug;123(8):956-9 [2899426.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Apr;40(4):720-3 [165216.001]
  • [Cites] Am J Med. 1969 Oct;47(4):648-52 [4390418.001]
  • [Cites] Ann Dermatol Venereol. 1998 Mar;125(3):185-7 [9747245.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Forensic Sci Int. 2006 Jan 27;156(2-3):223-8 [15982839.001]
  • [Cites] Am J Gastroenterol. 1983 Apr;78(4):214-7 [6837545.001]
  • [Cites] Arch Intern Med. 1990 Nov;150(11):2384-5 [2241450.001]
  • [Cites] Drug Saf. 2006;29(4):277-302 [16569079.001]
  • [Cites] BMJ. 1990 Mar 3;300(6724):614 [2108780.001]
  • [Cites] Ann Fr Anesth Reanim. 1982;1(1):53-8 [7137665.001]
  • [Cites] JAMA. 1985 Mar 15;253(11):1609-10 [3919189.001]
  • [Cites] Anesthesiology. 1971 Jul;35(1):48-53 [4397352.001]
  • [Cites] South Med J. 1975 Jun;68(6):748, 753 [1135653.001]
  • [Cites] Drug Saf. 2006;29(11):1049-59 [17061910.001]
  • [Cites] Br J Anaesth. 1977 Oct;49(10):991-8 [921877.001]
  • [Cites] South Med J. 2003 Sep;96(9):914-7 [14513991.001]
  • [Cites] Anesth Analg. 1999 Jan;88(1):16-21 [9895059.001]
  • [Cites] Acta Clin Belg. 1979;34(5):296-7 [549418.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2859-66 [15181069.001]
  • [Cites] Ann Intern Med. 1981 Mar;94(3):358-9 [7224385.001]
  • [Cites] Arch Dis Child. 1978 Aug;53(8):676-7 [708107.001]
  • [Cites] Arch Intern Med. 1984 Jan;144(1):173-4 [6691755.001]
  • [Cites] Postgrad Med J. 1984 Feb;60(700):111-5 [6709540.001]
  • [Cites] Aust N Z J Psychiatry. 1997 Dec;31(6):889-91 [9483266.001]
  • [Cites] Postgrad Med J. 2000 Jan;76(891):39-40 [10622782.001]
  • [Cites] JAMA. 1984 Nov 23-30;252(20):2860-2 [6541713.001]
  • [Cites] Med Clin (Barc). 1979 Nov 25;73(9):371-3 [529872.001]
  • [Cites] Endocr Pract. 2006 Sep-Oct;12(5):568-71 [17002933.001]
  • [Cites] Am J Emerg Med. 2005 Jul;23(4):565-6 [16032634.001]
  • [Cites] Lancet. 1977 Mar 26;1(8013):703 [66502.001]
  • [Cites] Anesth Analg (Paris). 1979 Mar-Apr;36(3-4):155-8 [484883.001]
  • [Cites] Lancet. 1978 Jun 10;1(8076):1259 [78019.001]
  • [Cites] Radiat Med. 2005 Mar;23 (2):133-8 [15827533.001]
  • [Cites] Am Heart J. 1991 Feb;121(2 Pt 1):610-3 [1990775.001]
  • [Cites] Ann Clin Res. 1982 Feb;14(1):15-26 [6182834.001]
  • [Cites] Am J Med. 1990 Dec;89(6):824-5 [2174647.001]
  • [Cites] J Am Osteopath Assoc. 1979 Jan;78(5):332-5 [759417.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Mar;62(3):577-82 [3003144.001]
  • [Cites] Eur J Pediatr Surg. 2000 Apr;10(2):142-4 [10877087.001]
  • (PMID = 17973541.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Catecholamines
  • [Number-of-references] 293
  •  go-up   go-down


8. Hoshi N, Sugino T, Suzuki T: Expression of endothelin system in neuroblastic tumors: close association of endothelin-1 and endothelin B receptor expression with differentiation of tumor cells. Med Mol Morphol; 2009 Jun;42(2):110-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelin system in neuroblastic tumors: close association of endothelin-1 and endothelin B receptor expression with differentiation of tumor cells.
  • We immunohistochemically examined for localization of ET-1, ET-3, ET-A receptor (ET-A), and ET-B receptor (ET-B) in 24 ganglioneuromas, 8 ganglioneuroblastomas, 37 neuroblastomas, 14 normal sympathetic ganglia, and 10 fetal adrenal glands with regard to neuroblastic cell differentiation.
  • Neuroblasts in fetal adrenal glands expressed ET-B (100%) alone.
  • Expression of ET-1 and ET-B was closely associated with tumor cell differentiation: the expression frequency of ET-1 or ET-B was 16% or 46% in neuroblastomas; 100% or 88% in ganglioneuroblastomas; and 96% or 92% in ganglioneuromas.
  • In contrast, ET-3 and ET-A showed no association with tumor cell differentiation: the expression frequency of ET-3 or ET-A was 26% or 14% in neuroblastomas; 63% or 13% in ganglioneuroblastomas; and 29% or 21% in ganglioneuromas.
  • [MeSH-major] Adrenal Gland Neoplasms / chemistry. Endothelin-1 / analysis. Ganglioneuroblastoma / chemistry. Neuroblastoma / chemistry. Receptor, Endothelin B / analysis
  • [MeSH-minor] Adrenal Glands / chemistry. Adrenal Glands / pathology. Adult. Cell Differentiation. Endothelin-3 / analysis. Endothelins. Fetus. Ganglia, Sympathetic / chemistry. Ganglia, Sympathetic / embryology. Humans. Neurons / chemistry. Neurons / pathology. Receptor, Endothelin A / analysis. Stem Cells / chemistry. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1990 Apr 30;168(2):537-43 [1692210.001]
  • [Cites] J Neurochem. 1997 Feb;68(2):570-7 [9003042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Oct;86(19):7634-8 [2678110.001]
  • [Cites] Biochem Biophys Res Commun. 1994 May 30;201(1):449-57 [8198607.001]
  • [Cites] J Clin Invest. 1998 Feb 1;101(3):549-59 [9449687.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] Pathol Int. 1997 Aug;47(8):540-6 [9293534.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1048-53 [16741047.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] Med Mol Morphol. 2008 Sep;41(3):151-9 [18807141.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7 [8632985.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3011-4 [1317255.001]
  • [Cites] Pharmacol Rev. 1994 Sep;46(3):325-415 [7831383.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):734-9 [8645250.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1277-85 [8001160.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103 Suppl 48:35S-38S [12193050.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):730-2 [2175396.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Feb;256(2):628-33 [1847205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9645-50 [8790384.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):663-8 [8630991.001]
  • [Cites] Histochemistry. 1991;95(3):303-14 [2050550.001]
  • [Cites] J Cardiovasc Pharmacol. 1993;22 Suppl 8:S121-4 [7509921.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):142-6 [11464869.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):732-5 [2175397.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):18352-7 [1917960.001]
  • [Cites] Proc Soc Exp Biol Med. 1992 Feb;199(2):165-70 [1741408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863-7 [2649896.001]
  • [Cites] Br J Pharmacol. 1991 Nov;104(3):750-4 [1665749.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103 Suppl 48:322S-326S [12193114.001]
  • [Cites] Oncology. 2001;60(3):258-67 [11340378.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):141-7 [2195059.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1306-11 [9102218.001]
  • (PMID = 19536618.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelin-3; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B
  •  go-up   go-down


9. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA: Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes; 2007 Nov;115(10):694-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm.
  • To our knowledge, no reported case of adrenal metastases with abdominal carcinomatosis secondary to HCC of the thyroid has been demonstrated by F-18 FDG PET/CT imaging.
  • One report of adrenal uptake on I-131 whole-body scan with HCC exists.
  • In this case report, we describe a patient with HCC who had a left adrenal metastasis with abdominal carcinomatosis that was discovered using F-18 FDG PET/CT imaging.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenoma, Oxyphilic / radiography. Adrenal Gland Neoplasms / radiography. Carcinoma / radiography. Positron-Emission Tomography. Thyroid Neoplasms / radiography
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058606.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. International Pediatric Endosurgery Group: IPEG guidelines for the surgical treatment of adrenal masses in children. J Laparoendosc Adv Surg Tech A; 2010 Mar;20(2):vii-ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IPEG guidelines for the surgical treatment of adrenal masses in children.
  • Laparoscopic adrenalectomy and adrenal biopsy are technically feasible in children.
  • There are no absolute contraindications to the laparoscopic approach, but for neuroblastomas and other adrenal neoplasms, care must be taken to maintain the principles of cancer surgery.
  • As opposed to adults, there are fewer benign indications for adrenalectomy, but in selected cases, laparoscopic resection of the adrenal is feasible.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods
  • [MeSH-minor] Biopsy / methods. Child. Evidence-Based Medicine. Humans. Neuroblastoma / diagnosis. Neuroblastoma / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230240.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


11. Naito M, Usui T, Tamanaha T, Kawashima ST, Iogawa H, Hagiwara H, Kimura T, Tagami T, Kurosawa M, Shimatsu A, Naruse M: R27X nonsense mutation of the SDHB gene in a patient with sporadic malignant paraganglioma. Endocrine; 2009 Aug;36(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R27X nonsense mutation of the SDHB gene in a patient with sporadic malignant paraganglioma.
  • It has been estimated that approximately 10% of pheochromocytomas and paragangliomas are part of a hereditary syndrome.
  • Here, we report a case of malignant paraganglioma with no apparent family history.
  • As recently described, SDHB mutations may cause extra-adrenal and malignant paragangliomas, such as in the present case.
  • [MeSH-major] Codon, Nonsense. Neoplasms, Multiple Primary / genetics. Paraganglioma / genetics. Peripheral Nervous System Neoplasms / genetics. Succinate Dehydrogenase / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]
  • [Cites] Endocr J. 2008 May;55(2):299-303 [18362451.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):1109-17 [16951005.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):153-9 [14685938.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):779-86 [17200167.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:104-11 [17102077.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23 (34):8812-8 [16314641.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):935-56 [18045948.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1035-7 [8772572.001]
  • [Cites] JAMA. 1995 Oct 11;274(14 ):1149-51 [7563486.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2125-31 [9179058.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Mar;68(3):494-5 [17970772.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):790-2 [16522703.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4101-5 [12213855.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Dec;65(6):699-705 [17121518.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Mar;29(1):159-85, x [10732270.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] J Urol. 1999 Nov;162(5):1582-6 [10524872.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33 [14974914.001]
  • [Cites] Horm Res. 2007;68(2):68-71 [17308434.001]
  • (PMID = 19415531.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


12. Hamanaka W, Yoneda S, Shirakusa T, Shirahama H, Tashiro Y, Iwasaki A, Shiraishi T, Tsuru H: Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case. Surg Today; 2008;38(3):275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case.
  • Instead of a large metastatic lung tumor with hemothorax and the existence of metastases in other organs, combined therapy of repeated resections for metastases and adjuvant therapy allowed for almost a 36-month survival following the first recurrence and a good quality of life.
  • In addition, a blood and pathological study revealed that the tumor in this case was an alpha-fetoprotein-producing ACC, which is, as far as we could ascertain, the first case of its kind.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Pneumonectomy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Surgery. 1986 Dec;100(6):1170-7 [3787475.001]
  • [Cites] Int J Urol. 2003 Aug;10(8):445-8 [12887367.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] J Natl Med Assoc. 2001 Jan;93(1):37-9 [12653379.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):457-61 [1706914.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] Surgery. 1991 Dec;110(6):1006-13 [1745969.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] World J Surg. 2001 Jun;25(6):735-8 [11376408.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2929-31 [12926137.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Hinyokika Kiyo. 1994 May;40(5):411-4 [7517622.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • (PMID = 18307006.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Whirledge S, Cidlowski JA: Glucocorticoids, stress, and fertility. Minerva Endocrinol; 2010 Jun;35(2):109-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modifications of the hypothalamo-pituitary-adrenal axis and associated changes in circulating levels of glucocorticoids form a key component of the response of an organism to stressful challenges.
  • 2) the pituitary gland (to inhibit the synthesis and release of luteinizing hormone [LH] and follicle stimulating hormone [FSH]);.
  • Furthermore, maternal exposure to prenatal stress or exogenous glucocorticoids can lead to permanent modification of hypothalamo-pituitary-adrenal function and stress-related behaviors in offspring.
  • [MeSH-major] Fertility. Glucocorticoids / metabolism. Hypothalamo-Hypophyseal System / metabolism. Pituitary-Adrenal System / metabolism. Stress, Physiological. Stress, Psychological / metabolism

  • MedlinePlus Health Information. consumer health - Steroids.
  • MedlinePlus Health Information. consumer health - Stress.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 1996 Nov;137(11):5090-5 [8895383.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):201-4 [9020850.001]
  • [Cites] Mol Cell Endocrinol. 1997 Mar 28;127(2):121-8 [9099907.001]
  • [Cites] Endocrinology. 1997 Jun;138(6):2435-42 [9165033.001]
  • [Cites] Fertil Steril. 1997 Jul;68(1):48-53 [9207583.001]
  • [Cites] Mol Cell Endocrinol. 1997 Sep 19;132(1-2):43-52 [9324045.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5089-95 [9389487.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):2372-8 [9891005.001]
  • [Cites] Biol Reprod. 1999 Feb;60(2):234-40 [9915986.001]
  • [Cites] Biol Reprod. 1999 Feb;60(2):330-5 [9915998.001]
  • [Cites] Biol Reprod. 1999 Apr;60(4):929-36 [10084968.001]
  • [Cites] Hum Reprod. 1999 Jul;14(7):1806-10 [10402394.001]
  • [Cites] Endocrinology. 1999 Aug;140(8):3805-14 [10433242.001]
  • [Cites] Science. 1957 Dec 27;126(3287):1347 [13495470.001]
  • [Cites] J Mol Endocrinol. 2005 Apr;34(2):583-95 [15821118.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2657-64 [15761036.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4115-8 [15870120.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):345-52 [15893910.001]
  • [Cites] J Physiol. 2005 Aug 1;566(Pt 3):967-77 [15932885.001]
  • [Cites] Biol Psychiatry. 2005 Aug 1;58(3):211-7 [16084841.001]
  • [Cites] Early Hum Dev. 2005 Nov;81(11):917-26 [16169164.001]
  • [Cites] Biol Reprod. 2006 Feb;74(2):265-74 [16221988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2410-5 [16467147.001]
  • [Cites] Endocrinology. 2006 Mar;147(3):1087-93 [16293664.001]
  • [Cites] J Physiol. 2006 Apr 1;572(Pt 1):31-44 [16469780.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5921-31 [16959831.001]
  • [Cites] J Assist Reprod Genet. 2006 Sep-Oct;23(9-10):377-80 [17033937.001]
  • [Cites] Endocrinology. 2007 Feb;148(2):762-73 [17082263.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7386-93 [18794126.001]
  • [Cites] Int J Androl. 2008 Dec;31(6):557-64 [17651396.001]
  • [Cites] Endocrinology. 2008 Dec;149(12):6406-15 [18755800.001]
  • [Cites] Horm Behav. 2009 Feb;55(2):292-8 [19084531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11324-9 [19541621.001]
  • [Cites] Fertil Steril. 2009 Aug;92(2):703-8 [18722610.001]
  • [Cites] Mol Endocrinol. 2009 Nov;23(11):1726-45 [19812390.001]
  • [Cites] Folia Histochem Cytobiol. 2009;47(2):237-41 [19995710.001]
  • [Cites] Steroids. 2010 Jan;75(1):1-12 [19818358.001]
  • [Cites] Reprod Toxicol. 2010 Apr;29(2):198-205 [19892010.001]
  • [Cites] J Clin Invest. 2010 Apr;120(4):963-72 [20364094.001]
  • [Cites] Immunology. 2007 Sep;122(1):47-53 [17451463.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):5769-79 [17872369.001]
  • [Cites] Steroids. 2008 Oct;73(9-10):1018-24 [18281069.001]
  • [Cites] J Cell Biochem. 2008 Aug 1;104(5):1671-83 [18335507.001]
  • [Cites] J Mol Endocrinol. 2008 Sep;41(3):165-75 [18596066.001]
  • [Cites] Eur J Pharmacol. 1999 Dec 10;386(1):69-74 [10611465.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):20204-9 [10777507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 28;275(2):661-7 [10964719.001]
  • [Cites] Hum Reprod. 2000 Sep;15(9):1917-20 [10966986.001]
  • [Cites] Endocr Rev. 2000 Oct;21(5):514-50 [11041447.001]
  • [Cites] Biol Reprod. 2000 Dec;63(6):1913-7 [11090465.001]
  • [Cites] Mol Cell Endocrinol. 2001 Feb 14;172(1-2):157-67 [11165049.001]
  • [Cites] Neuroendocrinology. 2001 May;73(5):302-11 [11399903.001]
  • [Cites] Endocrinology. 2002 Jan;143(1):130-8 [11751601.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2300-6 [12202416.001]
  • [Cites] Biol Reprod. 2002 Dec;67(6):1708-18 [12444044.001]
  • [Cites] Reproduction. 2002 Dec;124(6):801-12 [12530918.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jan 31;199(1-2):153-63 [12581887.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):127-35 [12844344.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3477-82 [12865328.001]
  • [Cites] FASEB J. 2003 Oct;17(13):1849-70 [14519664.001]
  • [Cites] Reproduction. 2003 Oct;126(4):425-41 [14525525.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1751-7 [14710109.001]
  • [Cites] J Comp Neurol. 2004 Apr 19;472(1):113-29 [15024756.001]
  • [Cites] J Endocrinol. 2004 Jun;181(3):509-13 [15171698.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4538-44 [15356059.001]
  • [Cites] J Androl. 2004 Nov-Dec;25(6):973-81 [15477372.001]
  • [Cites] Endocrinology. 1967 Mar;80(3):423-9 [5227344.001]
  • [Cites] J Endocrinol. 1969 Dec;45(4):515-23 [5366112.001]
  • [Cites] Recent Prog Horm Res. 1973;29:111-59 [4356273.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Jan;42(1):144-8 [1249181.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Aug;45(2):240-5 [195973.001]
  • [Cites] Endocrinology. 1977 Oct;101(4):1256-63 [198200.001]
  • [Cites] Steroids. 1978 Dec;32(5):639-48 [734698.001]
  • [Cites] Biol Reprod. 1980 Jun;22(5):1136-41 [7417646.001]
  • [Cites] Endocrinology. 1981 Jun;108(6):2142-8 [6262050.001]
  • [Cites] J Endocrinol. 1982 Oct;95(1):1-6 [7130885.001]
  • [Cites] Steroids. 1982 May;39(5):569-84 [6890727.001]
  • [Cites] Endocrinology. 1983 Oct;113(4):1356-63 [6311517.001]
  • [Cites] J Endocrinol Invest. 1984 Oct;7(5):529-37 [6439774.001]
  • [Cites] Endocrinology. 1985 Sep;117(3):849-54 [3926469.001]
  • [Cites] Biol Reprod. 1985 Sep;33(2):423-31 [3929850.001]
  • [Cites] Physiol Rev. 1986 Oct;66(4):1121-88 [3532143.001]
  • [Cites] Endocrinology. 1987 Aug;121(2):561-8 [3109884.001]
  • [Cites] J Biol Chem. 1987 Jun 15;262(17):8288-92 [3496332.001]
  • [Cites] Brain Res. 1988 Jul 1;470(1):119-27 [3409041.001]
  • [Cites] Adv Exp Med Biol. 1988;245:377-87 [3067563.001]
  • [Cites] Endocrinology. 1989 May;124(5):2099-104 [2539967.001]
  • [Cites] Endocr Rev. 1990 Feb;11(1):177-99 [2108012.001]
  • [Cites] Horm Behav. 1990 Sep;24(3):324-41 [2227847.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1429-35 [1874181.001]
  • [Cites] Endocrinology. 1991 Nov;129(5):2793-5 [1935811.001]
  • [Cites] Neuroendocrinology. 1991 Oct;54(4):313-20 [1758573.001]
  • [Cites] J Endocrinol. 1992 Oct;135(1):53-8 [1431683.001]
  • [Cites] Acta Endocrinol (Copenh). 1992 Nov;127(5):403-6 [1471451.001]
  • [Cites] Mol Cell Endocrinol. 1993 Feb;91(1-2):1-11 [8472841.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jun;38(6):641-4 [8334750.001]
  • [Cites] Mol Cell Endocrinol. 1993 Sep;95(1-2):115-20 [8243801.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1467-74 [8119188.001]
  • [Cites] Mol Cell Endocrinol. 1994 Nov;105(2):R11-7 [7859916.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Nature. 1995 Sep 7;377(6544):68-71 [7659164.001]
  • [Cites] Eur J Immunol. 1995 Dec;25(12):3277-84 [8566012.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;774:217-31 [8597461.001]
  • (PMID = 20595939.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ NIHMS403039; NLM/ PMC3547681
  •  go-up   go-down


14. Kim KP, Kim MH, Kim JC, Lee SS, Seo DW, Lee SK: Diagnostic criteria for autoimmune chronic pancreatitis revisited. World J Gastroenterol; 2006 Apr 28;12(16):2487-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Above all, AIP is a very attractive disease to clinicians in terms of its dramatic response to the oral steroid therapy in contrast to ordinary chronic pancreatitis.
  • In the year 2002, the Japan Pancreas Society published the diagnostic criteria of AIP and many clinicians around the world use these criteria for the diagnosis of AIP.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Pancreatitis, Chronic / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Immunoglobulin G / blood. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(4):333-42 [10664278.001]
  • [Cites] Gastrointest Endosc. 2003 Oct;58(4):510-5 [14520282.001]
  • [Cites] Pancreas. 2000 May;20(4):382-8 [10824693.001]
  • [Cites] Dig Dis Sci. 2003 Sep;48(9):1705-8 [14560987.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1557-8 [14628815.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2694-9 [14687819.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2811-2 [14687846.001]
  • [Cites] Pancreas. 2004 Jan;28(1):105-7 [14707740.001]
  • [Cites] Korean J Gastroenterol. 2004 Feb;43(2):112-9 [14978368.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1214 [15057766.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1605-16 [15307882.001]
  • [Cites] Med J Aust. 1969 Mar 29;1(13):696-9 [4890055.001]
  • [Cites] Acta Gastroenterol Belg. 1985 Nov-Dec;48(6):579-82 [3837584.001]
  • [Cites] Gastrointest Radiol. 1987;12(1):18-22 [3792751.001]
  • [Cites] Radiol Clin North Am. 1989 Jan;27(1):39-50 [2642274.001]
  • [Cites] Cancer. 1990 Feb 15;65(4):893-6 [2297660.001]
  • [Cites] Acta Radiol. 1990 Sep;31(5):483-8 [2261295.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):387-95 [2050373.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2060-2 [7942737.001]
  • [Cites] Dig Dis Sci. 1995 Jul;40(7):1561-8 [7628283.001]
  • [Cites] Hosp Pract (1995). 1997 Apr 15;32(4):147-54 [9109812.001]
  • [Cites] JOP. 2004 Nov;5(6):527-30 [15536296.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):721-31 [15557948.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1265-8 [15618830.001]
  • [Cites] Pancreas. 2005 Jan;30(1):20-5 [15632695.001]
  • [Cites] Pancreas. 2005 Jan;30(1):76-82 [15632703.001]
  • [Cites] Pancreas. 2005 Jan;30(1):83-6 [15632704.001]
  • [Cites] Gut. 2005 Feb;54(2):274-81 [15647194.001]
  • [Cites] JOP. 2005 Jan;6(1 Suppl):89-96 [15650291.001]
  • [Cites] JOP. 2005 Jan;6(1 Suppl):97-101 [15650292.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):401-6 [15758911.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):467-72 [15758927.001]
  • [Cites] Pancreas. 2005 Apr;30(3):272-8 [15782107.001]
  • [Cites] Gut. 2005 May;54(5):581-3 [15831898.001]
  • [Cites] Gut. 2005 May;54(5):703-9 [15831920.001]
  • [Cites] Pancreas. 2005 May;30(4):355-8 [15841047.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1626-41 [15887155.001]
  • [Cites] Am J Gastroenterol. 1998 Feb;93(2):260-3 [9468255.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1323-7 [9574610.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):43-4 [10406367.001]
  • [Cites] Radiology. 2004 Nov;233(2):345-52 [15459324.001]
  • [Cites] JOP. 2004 Nov;5(6):488-90 [15536287.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):682-707 [11179244.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):732-8 [11236777.001]
  • [Cites] J Gastroenterol. 2001 May;36(5):293-302 [11388391.001]
  • [Cites] J Gastroenterol. 2002;37(2):133-7 [11871765.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):494-9 [11923760.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1264-9 [11984513.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):889-96 [12024146.001]
  • [Cites] Radiology. 2002 Jun;223(3):603-13 [12034923.001]
  • [Cites] Gut. 2002 Jul;51(1):1-4 [12077078.001]
  • [Cites] Pancreatology. 2001;1(3):246-53 [12120203.001]
  • [Cites] Hepatology. 2002 Aug;36(2):479-97 [12143059.001]
  • [Cites] Pancreas. 2002 Oct;25(3):283-9 [12370540.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6 Suppl):S237-40 [12447274.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1229-42, v [12479708.001]
  • [Cites] Pancreas. 2003 Jan;26(1):92-4 [12499924.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):1155-8 [12809842.001]
  • [Cites] Pancreas. 2003 Jul;27(1):1-13 [12826899.001]
  • [Cites] Pancreas. 2003 Jul;27(1):14-9 [12826900.001]
  • [Cites] J Gastroenterol. 2003;38(6):603-7 [12856677.001]
  • [Cites] Dig Dis Sci. 2003 Aug;48(8):1465-71 [12924637.001]
  • [Cites] Pancreas. 2003 Oct;27(3):275-7 [14508137.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):573-81 [10702209.001]
  • (PMID = 16688792.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunoglobulin G
  • [Number-of-references] 74
  • [Other-IDs] NLM/ PMC4087979
  •  go-up   go-down


15. Thouennon E, Pierre A, Yon L, Anouar Y: Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma. Cell Mol Neurobiol; 2010 Nov;30(8):1383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are catecholamine-producing tumors arising from chromaffin cells of the adrenal medulla or extra-adrenal location.
  • Along with catecholamines, tumoral cells produce and secrete elevated quantities of trophic peptides which are normally released in a regulated manner by the normal adrenal medulla.
  • Here, we review the expression levels of NPY, PACAP, and AM and theirs receptors in chromaffin cells and pheochromocytomas, and address their possible implication in the adrenal medulla tumorigenesis and malignant development of pheochromocytomas.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Chromaffin Cells / metabolism. Neuropeptides / metabolism. Pheochromocytoma / metabolism. Receptors, Neuropeptide / metabolism

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R588-97 [12414436.001]
  • [Cites] Neuroscience. 1986 Nov;19(3):1011-22 [3540720.001]
  • [Cites] Nature. 1982 Apr 15;296(5858):659-60 [6896083.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1203-10 [14617572.001]
  • [Cites] Neuropeptides. 1989 Jan;13(1):35-41 [2922105.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2503-9 [7593641.001]
  • [Cites] Endocr J. 2005 Feb;52(1):1-10 [15758552.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3622-7 [9013614.001]
  • [Cites] Nature. 2001 Apr 19;410(6831):940-4 [11309620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40 [17898181.001]
  • [Cites] Neuropeptides. 2004 Aug;38(4):141-51 [15337367.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8426-33 [15623622.001]
  • [Cites] Neuropeptides. 2004 Aug;38(4):175-88 [15337370.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Mar 5;87(2):175-83 [11245919.001]
  • [Cites] Front Neuroendocrinol. 2008 Jan;29(1):128-41 [18048093.001]
  • [Cites] Eur J Neurosci. 2003 Jan;17(1):71-82 [12534970.001]
  • [Cites] J Endocrinol. 2007 May;193(2):225-33 [17470513.001]
  • [Cites] Ann N Y Acad Sci. 2006 Jul;1070:440-9 [16888207.001]
  • [Cites] Ann N Y Acad Sci. 2000;921:429-33 [11193870.001]
  • [Cites] J Clin Invest. 2003 Jun;111(12):1853-62 [12813021.001]
  • [Cites] Regul Pept. 2004 Dec 15;123(1-3):29-32 [15518890.001]
  • [Cites] EXS. 2006;(95):7-33 [16382995.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10497-502 [16798884.001]
  • [Cites] Peptides. 2007 Feb;28(2):426-34 [17204352.001]
  • [Cites] J Cell Physiol. 2008 Apr;215(1):122-8 [17941085.001]
  • [Cites] Neuropeptides. 1996 Dec;30(6):572-82 [9004256.001]
  • [Cites] Regul Pept. 2003 Apr 15;112(1-3):27-31 [12667622.001]
  • [Cites] Can J Physiol Pharmacol. 2003 Feb;81(2):89-94 [12710520.001]
  • [Cites] Ann N Y Acad Sci. 1998 Dec 11;865:533-6 [9928064.001]
  • [Cites] Regul Pept. 1995 Aug 22;58(3):89-98 [8577931.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003.001]
  • [Cites] J Mol Neurosci. 1997 Oct;9(2):127-40 [9407393.001]
  • [Cites] Eur J Neurosci. 2002 May;15(9):1485-92 [12028358.001]
  • [Cites] Hypertens Res. 2003 Feb;26 Suppl:S71-8 [12630814.001]
  • [Cites] Pharmacol Res. 2008 Jul;58(1):52-7 [18639636.001]
  • [Cites] Peptides. 1999 Dec;20(12):1479-87 [10698124.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 29;250(3):689-93 [9784407.001]
  • [Cites] Ann N Y Acad Sci. 2006 Jul;1070:309-12 [16888183.001]
  • [Cites] Peptides. 2001 Nov;22(11):1895-901 [11754978.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3105-12 [10850463.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60 [8387282.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):293-302 [16513255.001]
  • [Cites] Clin Sci (Lond). 1999 May;96(5):493-8 [10209081.001]
  • [Cites] Neurochem Int. 1993 Jul;23(1):71-7 [8369734.001]
  • [Cites] Regul Pept. 2003 Apr 15;112(1-3):175-83 [12667640.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7010-4 [2582442.001]
  • [Cites] Int J Mol Med. 2005 Jan;15(1):3-13 [15583821.001]
  • [Cites] J Auton Nerv Syst. 1983 Nov;9(2-3):559-63 [6689331.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1833-5 [2208039.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1663-70 [12429744.001]
  • [Cites] Cancer Lett. 2004 Mar 18;205(2):189-95 [15036651.001]
  • [Cites] J Neurochem. 1999 Oct;73(4):1769-72 [10501227.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1719-28 [15753367.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1299-305 [9543159.001]
  • [Cites] Can J Physiol Pharmacol. 2003 Feb;81(2):177-85 [12710532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):461-6 [11756684.001]
  • [Cites] Regul Pept. 2003 Feb 28;110(3):213-7 [12573802.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5956-63 [11739470.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 2):R1118-24 [10198393.001]
  • [Cites] Neuroendocrinology. 1995 Jan;61(1):85-8 [7731501.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):365-9 [8483815.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):635-43 [17100569.001]
  • [Cites] Regul Pept. 2006 Nov 15;137(1-2):79-88 [16963134.001]
  • [Cites] Pharmacol Rev. 2009 Sep;61(3):283-357 [19805477.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4865-72 [17878247.001]
  • [Cites] Neurosci Lett. 1983 Dec 23;43(1):79-84 [6689442.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1766-72 [10737636.001]
  • [Cites] J Mol Neurosci. 2008 Nov;36(1-3):26-37 [18506634.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun 25;17(3):637-51 [20483910.001]
  • (PMID = 21046451.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Receptors, Neuropeptide
  •  go-up   go-down


16. Aarts M, Dannenberg H, deLeeuw RJ, van Nederveen FH, Verhofstad AA, Lenders JW, Dinjens WN, Speel EJ, Lam WL, de Krijger RR: Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer; 2006 Jan;45(1):83-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas (PCC) are relatively rare neuroendocrine tumors, mainly of the adrenal medulla.
  • They arise sporadically or occur secondary to inherited cancer syndromes, such as multiple endocrine neoplasia type II (MEN2), von Hippel-Lindau disease (VHL), or neurofibromatosis type I (NF1).
  • In conclusion, these data strongly suggest that chromosome arm 1p is the site for multiple tumor suppressor genes, although the potential candidate genes CDKN2C and PTPRF/LAR are not included in these regions.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosome Deletion. Chromosomes, Artificial, Bacterial. Chromosomes, Human, Pair 1 / genetics. Pheochromocytoma / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16215979.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S: Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol; 2009 Oct;161(4):513-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?
  • OBJECTIVE: To assess the performance of current clinical recommendations for the evaluation of an adrenal incidentaloma.
  • Eligible studies were those deemed most applicable to the clinical scenario of a patient referred to an endocrinologist for assessment of an incidentally detected adrenal mass.
  • RESULTS: The prevalence of functional and malignant lesions presenting as adrenal incidentaloma was similar to that quoted in most reviews, other than a lower incidence of adrenal carcinoma (1.9 vs 4.7%) and metastases (0.7 vs 2.3%).
  • The development of functionality or malignancy during follow-up was rare (<1% becoming functional and 0.2% becoming malignant).
  • The average recommended computed tomography (CT) scan follow-up exposes each patient to 23 mSv of ionising radiation, equating to a 1 in 430 to 2170 chance of causing fatal cancer.
  • This is similar to the chance of developing adrenal malignancy during 3-year follow-up of adrenal incidentaloma.
  • CONCLUSION: Current recommendations for evaluation of adrenal incidentaloma are likely to result in significant costs, both financial and emotional, due to high false-positive rates.
  • The dose of radiation involved in currently recommended CT scan follow-up confers a risk of fatal cancer that is similar to the risk of the adrenal becoming malignant.


18. Bowes T, Singh B, Gupta RS: Subcellular localization of fumarase in mammalian cells and tissues. Histochem Cell Biol; 2007 Mar;127(3):335-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In thin sections from kidney, liver, heart, adrenal gland and anterior pituitary, strong and specific labeling due to fumarase antibody was only detected in mitochondria.
  • Although the cellular function of fumarase at these extramitochondrial locations is not known, the appearance/localization of fumarase outside mitochondria may help explain how mutations in this mitochondrial protein can give rise to a number of different types of cancers.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jun;77(6):3430-4 [6997878.001]
  • [Cites] Cell Biol Int. 2001;25(4):331-8 [11319839.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20887-95 [10770938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5 [15024130.001]
  • [Cites] Rev Reprod. 1996 Jan;1(1):28-32 [9414435.001]
  • [Cites] Trends Biochem Sci. 2000 Nov;25(11):555-60 [11084368.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):6972-8 [9843503.001]
  • [Cites] Cell Stress Chaperones. 2006 Summer;11(2):116-28 [16817317.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1003-14 [8862516.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):686-93 [12507504.001]
  • [Cites] J Assist Reprod Genet. 1997 Oct;14(9):492-5 [9401863.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92 (21):9866-70 [7568234.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):911-8 [16774737.001]
  • [Cites] Cell Stress Chaperones. 2002 Oct;7(4):317-29 [12653476.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):32056-63 [11350955.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31544-55 [15155745.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):539-49 [7911805.001]
  • [Cites] Biochem J. 1990 Nov 15;272(1):119-26 [2264815.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):551-60 [7912672.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10425-30 [9724719.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3305-12 [10652318.001]
  • [Cites] J Biochem. 1984 Jul;96(1):189-95 [6333419.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):45-56 [10653585.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):30-9 [11010808.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:423-7 [10642497.001]
  • [Cites] Immunol Rev. 2001 Apr;180:65-77 [11414365.001]
  • [Cites] Histochem Cell Biol. 2005 Nov;124(5):409-21 [16133117.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45109-16 [12960177.001]
  • [Cites] DNA Cell Biol. 1992 Jul-Aug;11(6):489-96 [1524681.001]
  • [Cites] Expert Rev Mol Med. 2000 Sep 15;2(8):1-17 [14585136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6237-42 [15069201.001]
  • [Cites] Mol Genet Metab. 1998 Apr;63(4):254-62 [9635293.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 18;275(1):174-9 [10944461.001]
  • [Cites] Histochem Cell Biol. 2000 Sep;114(3):245-55 [11083468.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3869-76 [10207110.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):23157-61 [7901206.001]
  • [Cites] Int Rev Cytol. 2000;194:133-96 [10494626.001]
  • [Cites] Mitochondrion. 2004 May;3(6):315-25 [16120363.001]
  • [Cites] Exp Cell Res. 2003 May 15;286(1):96-101 [12729798.001]
  • [Cites] Exp Cell Res. 1996 Jan 10;222(1):16-27 [8549659.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25587-93 [9748223.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2581-6 [2914923.001]
  • [Cites] Circ Res. 1994 Dec;75(6):1078-85 [7525102.001]
  • [Cites] Biochem Soc Trans. 2006 Jun;34(Pt 3):370-3 [16709164.001]
  • [Cites] Trends Biochem Sci. 1999 May;24(5):174-7 [10322429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46111-7 [11585823.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):353-64 [11962739.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar;281(5):1161-9 [11243856.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):193-202 [12612654.001]
  • [Cites] Eur J Cell Biol. 2003 May;82(5):240-52 [12800979.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G894-902 [8238519.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):306-12 [16278343.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):215-26 [12533530.001]
  • [Cites] J Histochem Cytochem. 1996 Jul;44(7):743-9 [8675995.001]
  • [Cites] Mol Gen Genet. 1991 Oct;229(3):413-20 [1944230.001]
  • [Cites] J Cell Biol. 1967 Aug;34(2):597-615 [6035648.001]
  • [Cites] Exp Cell Res. 1997 Aug 1;234(2):205-16 [9260887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):858-62 [7905632.001]
  • [Cites] Eur J Biochem. 1992 Jul 15;207(2):767-72 [1633825.001]
  • [Cites] Trends Cell Biol. 1992 Dec;2(12):369-75 [14731958.001]
  • [Cites] Cell. 1990 Mar 23;60(6):971-80 [2317868.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4770-8 [8007976.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1439-48 [12006643.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):17-22 [14695314.001]
  • [Cites] Histochem Cell Biol. 2001 Dec;116(6):507-17 [11810192.001]
  • (PMID = 17111171.001).
  • [ISSN] 0948-6143
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Indicators and Reagents; EC 4.2.1.2 / Fumarate Hydratase; KOO5CM684H / Digitonin
  •  go-up   go-down


19. Madani R, Al-Hashmi M, Bliss R, Lennard TW: Ectopic pheochromocytoma: does the rule of tens apply? World J Surg; 2007 Apr;31(4):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The rule of "tens" is often stated to reflect the distribution and histology of pheochromocytomas, with 10% being bilateral, 10%; ectopic in origin, and 10%; malignant.
  • RESULTS: In total, 77 patients had pheochromocytomas: 75%; (58/77) adrenal and 25%; (19/77) ectopic.
  • Of the adrenal pheochromocytomas, 10%; (6/58) were bilateral.
  • The anatomic locations of the ectopic pheochromocytomas were as follows: 26%; (5/19) adjacent to the adrenals, 53%; (10/19) in the organ of Zuckerkandl, 11%; (2/19) in the bladder, 5%; (1/19) in the mediastinum, and 5%;(1/19) in the neck.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Pheochromocytoma / pathology. Pheochromocytoma / surgery


20. Rice JM: The carcinogenicity of acrylamide. Mutat Res; 2005 Feb 7;580(1-2):3-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two bioassays in rats, acrylamide administered in drinking water consistently induced peritesticular mesotheliomas, thyroid follicular cell tumors, and mammary gland tumors, as well as primary brain tumors when all such tumors were included in data analysis.
  • In one of the rat bioassays, increased numbers of adrenal pheochromocytomas, adenomas of pituitary and clitoral glands, papillomas of the oral cavity, and adenocarcinomas of the uterus also occurred.
  • Epidemiologic studies of possible health effects from exposures to acrylamide have not produced consistent evidence of increased cancer risk, in either occupationally exposed workers or the general populations of several countries in which acrylamide is present in certain foods and beverages.
  • A doubling of risk for pancreatic cancer was observed in the most highly exposed workers within the largest industrial cohort, but no consistent exposure-response relationships were identified.
  • Retrospective re-analyses of previously conducted case-control studies of cancer incidence in several European populations have identified no causal relationship between consumption of foods or beverages that contain acrylamide and the incidence of cancers at various sites including kidney, large bowel, urinary bladder, oral cavity, pharynx, larynx, esophagus, breast, and ovary.
  • These retrospective studies of cancer incidence in relation to acrylamide in food have limited power to detect increased cancer risks, and have been criticized on various grounds, but they do indicate that no major cancer risks are attributable to intake of acrylamide in Western diets.
  • [MeSH-major] Acrylamide. Carcinogens. Neoplasms / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Animals. Food Contamination. Humans. Neoplasms, Experimental / chemically induced. Risk

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACRYLAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668103.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 20R035KLCI / Acrylamide
  • [Number-of-references] 72
  •  go-up   go-down


21. Merchant S, Huang N, Korbelik M: Expression of complement and pentraxin proteins in acute phase response elicited by tumor photodynamic therapy: the engagement of adrenal hormones. Int Immunopharmacol; 2010 Dec;10(12):1595-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of complement and pentraxin proteins in acute phase response elicited by tumor photodynamic therapy: the engagement of adrenal hormones.
  • The results show a distinct pattern of changes in the expression of genes encoding these proteins in the tumor, as well as host liver and spleen, following PDT mediated by photosensitizer Photofrin™.
  • A direct demonstration that tumor PDT induces glucocorticoid hormone upregulation is provided by documenting elevated levels of serum corticosterone in mice bearing PDT-treated LLC tumors.
  • Tumor response to PDT was negatively affected by blocking glucocorticoid receptor activity, which suggests that glucocorticoid hormones have a positive impact on the therapeutic outcome with this therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20933626.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Photosensitizing Agents; 0 / neuronal pentraxin; 9007-36-7 / Complement System Proteins; 9007-41-4 / C-Reactive Protein; 97067-70-4 / Dihematoporphyrin Ether; W980KJ009P / Corticosterone
  •  go-up   go-down


22. Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM: Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol; 2010 Nov;225(3):822-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Development of cisplatin resistance in cancer cells appears to be a consequence of multiple epigenetic alterations in genes involved in DNA damage repair, proto-oncogenes, apoptosis, transporters, transcription factors, etc.
  • Analysis of TMEM205 expression profiles in normal human tissues indicates a differential expression pattern with higher expression levels in the liver, pancreas, and adrenal glands.
  • These results indicate that a novel mechanism for cisplatin resistance is mediated by TMEM205, and also suggest that overexpression of TMEM205 in CP-r cells may be valuable as a biomarker or target in cancer chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / metabolism. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Membrane Proteins / metabolism. Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1153-60 [11723219.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903 [12477932.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5909-16 [14522917.001]
  • [Cites] Genome Res. 2003 Oct;13(10):2265-70 [12975309.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1403-10 [14973057.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6837-49 [15254249.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2056-61 [3828995.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):68-73 [3335000.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):1109-15 [1457352.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):268-75 [9443404.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1149-58 [15726096.001]
  • [Cites] Nat Rev Drug Discov. 2005 Apr;4(4):307-20 [15789122.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1383-8 [16394183.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Sep;58(3):384-95 [16404635.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31 [17336087.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2782-7 [17998803.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:495-535 [17937596.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):425-33 [18199536.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1116-20 [18264087.001]
  • (PMID = 20589834.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010830-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / TMEM205 protein, human; 0 / TMEM205 protein, mouse; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS244910; NLM/ PMC2971691
  •  go-up   go-down


23. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB, Drake WM, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL: Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer; 2009 Jun;16(2):515-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present retrospective study was to compare the clinical phenotypes of disease in subjects developing chromaffin tumours as a result of SDHB mutations or VHL disease.
  • Thirty-one subjects with chromaffin tumours were assessed; 16 subjects had SDHB gene mutations and 15 subjects had a diagnosis of VHL.
  • VHL-related tumours were predominantly adrenal phaeochromocytomas (22/26; 84.6%), while SDHB-related tumours were predominantly extra-adrenal paragangliomas (19/25; 76%).
  • Median age at onset of the first chromaffin tumour was similar in the two cohorts.
  • Tumour size was significantly larger in the SDHB cohort in comparison with the VHL cohort (P=0.002).
  • Multifocal disease was present in 9/15 (60%) of the VHL cohort (bilateral phaeochromocytomas) and only 3/16 (19%) of the SDHB cohort, while metastatic disease was found in 5/16 (31%) of the SDHB cohort but not in the VHL cohort to date.
  • Renal cell carcinomas were a feature in 5/15 (33%) of the VHL cohort and 1/16 (6%) of the SDHB cohort.
  • These data indicate that SDHB-related tumours are predominantly extra-adrenal in location and associated with higher catecholamine secretion and more malignant disease, in subjects who appear more symptomatic.
  • VHL-related tumours tend to be adrenal phaeochromocytomas, frequently bilateral and associated with a milder phenotype.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Paraganglioma, Extra-Adrenal / genetics. Pheochromocytoma / genetics. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208735.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


24. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L: Medical management of patients with brain tumors. J Neurooncol; 2006 Dec;80(3):313-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common medical problems in brain tumor patients include the management of seizures, peritumoral edema, medication side effects, venous thromboembolism (VTE), fatigue and cognitive dysfunction.
  • There is increasing evidence that brain tumor patients who have not had a seizure do not benefit from prophylactic antiepileptic medications.
  • There is also growing evidence suggesting that anticoagulation may be more effective than inferior vena cava IVC) filtration devices for treating VTE in brain tumor patients and the risk of hemorrhage with anticoagulation is relatively small.
  • [MeSH-major] Brain Edema / etiology. Brain Neoplasms / complications. Epilepsy / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Anticoagulants / therapeutic use. Anticonvulsants / therapeutic use. Cognition Disorders / etiology. Cognition Disorders / therapy. Depressive Disorder / etiology. Depressive Disorder / therapy. Fatigue / etiology. Fatigue / therapy. Humans. Patient Care Planning

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1998 Sep;16(3):193-8 [9769622.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):263-70 [12892232.001]
  • [Cites] Neurology. 2005 Jun 28;64(12 Suppl 3):S2-11 [15994220.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1352-60 [8640825.001]
  • [Cites] Arch Neurol. 1998 May;55(5):705-10 [9605728.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):753-7 [1402964.001]
  • [Cites] Am J Med. 1989 Nov;87(5):505-10 [2683764.001]
  • [Cites] Palliat Med. 2002 May;16(3):261-3 [12047006.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):263-78 [9258818.001]
  • [Cites] Curr Treat Options Neurol. 2005 Jul;7(4):323-336 [15967095.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2487-98 [15190141.001]
  • [Cites] N Engl J Med. 1976 Feb 26;294(9):473-9 [173997.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2621-4 [1933812.001]
  • [Cites] Neurosurg Focus. 2004 Oct 15;17(4):E3 [15633989.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):186-97 [15865884.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):311-5 [1732431.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):329-32 [8170176.001]
  • [Cites] Neurology. 1991 Aug;41(8):1235-9 [1866012.001]
  • [Cites] J Clin Neurosci. 2003 Jul;10 (4):467-9 [12852888.001]
  • [Cites] Cardiol Clin. 1988 Nov;6(4):537-45 [3067845.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):682-7 [8594426.001]
  • [Cites] Neurosurgery. 1990 Jul;27(1):74-6; discussion 77 [2377284.001]
  • [Cites] Cancer Invest. 2005;23(3):229-39 [15945509.001]
  • [Cites] Semin Respir Infect. 1998 Dec;13(4):296-303 [9872626.001]
  • [Cites] J Neurosurg. 1980 Mar;52(3):359-66 [7359190.001]
  • [Cites] Surg Neurol. 1981 Jul;16(1):23-4 [7280966.001]
  • [Cites] J Thromb Haemost. 2003 Jul;1(7):1456-63 [12871280.001]
  • [Cites] J Neurosurg. 1983 May;58(5):672-7 [6339686.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Curr Opin Anaesthesiol. 2006 Feb;19(1):44-51 [16547432.001]
  • [Cites] Clin Pharmacol Ther. 1997 May;61(5):503-8 [9164412.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):105-11 [15263050.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):210-5 [16096772.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1310-8 [16525187.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):291-302 [15667530.001]
  • [Cites] N Engl J Med. 1969 Jul 3;281(1):32-4 [5814988.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Eur Neurol. 2001;45(1):46-51 [11150841.001]
  • [Cites] Epilepsia. 1999 Mar;40(3):341-4 [10080516.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):373-7 [11861699.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):409-15 [9459643.001]
  • [Cites] Pharmacol Res. 2002 Sep;46(3):265-71 [12220970.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):211-5 [16193395.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):71-7 [9541686.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):578-91 [2564431.001]
  • [Cites] Epilepsia. 2002 Feb;43(2):175-82 [11903465.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] Oncology (Williston Park). 2005 Jul;19(8):1077-84; discussion 1084, 1087-8 [16131048.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1691-6 [15150608.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):380-6 [15578701.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):633-6 [15390288.001]
  • [Cites] J Neurooncol. 1994;22(2):87-100 [7745471.001]
  • [Cites] Can J Surg. 1983 Mar;26(2):181-3 [6825010.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):401-10 [15925818.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):435-46 [8823773.001]
  • [Cites] Ann Neurol. 1983 Mar;13(3):334-6 [6303201.001]
  • [Cites] Radiology. 2000 May;215(2):535-42 [10796937.001]
  • [Cites] N Engl J Med. 2003 Sep 25;349(13):1227-35 [14507948.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):705-10 [3908894.001]
  • [Cites] Neurosci Lett. 2001 Apr 20;302(2-3):154-6 [11290410.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] Annu Rev Neurosci. 1999;22:11-28 [10202530.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] J Neurooncol. 1992 Nov;14(3):243-53 [1460487.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):347-62 [15637647.001]
  • [Cites] Am J Med. 1999 Jun;106(6):660-9 [10378625.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):233-8 [8815566.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):493-8 [8293418.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):277-88 [9589201.001]
  • [Cites] Chest. 2001 Jan;119(1 Suppl):64S-94S [11157643.001]
  • [Cites] Epilepsia. 2001 Jun;42(6):714-8 [11422324.001]
  • [Cites] Annu Rev Med. 2005;56:63-77 [15660502.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 Jul;5(4):322-8 [15987617.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1772-8 [16116608.001]
  • [Cites] Ann Neurol. 1986 Apr;19(4):373-7 [3707089.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):1-15 [10664370.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1312-7 [14977830.001]
  • [Cites] JAMA. 1992 Feb 12;267(6):832-7 [1732656.001]
  • [Cites] Arch Neurol. 1991 Apr;48(4):406-9 [2012515.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1717-23 [15073862.001]
  • [Cites] Neurology. 1994 Apr;44(4):675-80 [8164824.001]
  • [Cites] Radiology. 1996 Sep;200(3):699-706 [8756918.001]
  • [Cites] J Chronic Dis. 1985;38(6):457-68 [3891768.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] Am J Med. 2001 Nov;111(7):541-5 [11705430.001]
  • [Cites] N Engl J Med. 1983 Jul 7;309(1):21-4 [6343871.001]
  • [Cites] Epilepsia. 2003 Sep;44(9):1223-32 [12919395.001]
  • [Cites] J Neurosurg. 1987 Mar;66(3):357-8 [3819830.001]
  • [Cites] Ann Neurol. 1986 Jun;19(6):592-5 [3729313.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1415-20 [16549835.001]
  • [Cites] J Intern Med. 1994 Dec;236(6):619-32 [7989897.001]
  • [Cites] Am J Med. 1993 Feb;94(2):216-9 [8381584.001]
  • [Cites] N Engl J Med. 1952 Apr 10;246(15):568-71 [14910860.001]
  • [Cites] Arch Neurol. 1995 Jul;52(7):717-24 [7619029.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Jul;274(1):270-5 [7616408.001]
  • [Cites] Ann Allergy. 1989 May;62(5):375-91 [2655506.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7 [14744282.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2):211-8 [15815967.001]
  • [Cites] Arch Intern Med. 1987 Dec;147(12):2177-9 [3500686.001]
  • [Cites] Cancer Treat Rev. 2003 Apr;29(2):105-19 [12670453.001]
  • [Cites] Expert Opin Biol Ther. 2005 Jun;5(6):817-32 [15952912.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4439-43 [14645434.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurooncol. 1994;22(2):127-37 [7745465.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1087-90 [6502166.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):372-90 [16465173.001]
  • [Cites] Immunol Allergy Clin North Am. 2005 Aug;25(3):451-68 [16054537.001]
  • [Cites] Ann Oncol. 2005 May;16(5):696-701 [15802275.001]
  • [Cites] Oncol Nurs Forum. 1999 Jun;26(5):921-5 [10382191.001]
  • [Cites] Ann Intern Med. 1991 May 1;114(9):735-40 [2012355.001]
  • [Cites] J Am Med Assoc. 1957 Apr 20;163(16):1473-6 [13415910.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):519-22 [2970013.001]
  • [Cites] Am J Med. 1980 Nov;69(5):657-66 [7435509.001]
  • [Cites] Oncologist. 2005 Jan;10(1):72-9 [15632254.001]
  • [Cites] Neurology. 1997 May;48(5):1234-8 [9153449.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):401S-428S [15383479.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):440-4 [9054958.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23 (27):6647-56 [16170172.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2327-32 [10927730.001]
  • [Cites] Horm Res. 2001;56 Suppl 1:24-8 [11786681.001]
  • [Cites] Acta Neurochir (Wien). 1990;103(1-2):47-51 [2360466.001]
  • [Cites] N Engl J Med. 2005 Sep 8;353(10 ):1028-40 [16148288.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):235-40 [8847557.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):511-7 [15509484.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Neuro Oncol. 2002 Jan;4(1):22-5 [11772429.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10 ):657-62 [9280815.001]
  • [Cites] Semin Vasc Med. 2005 Nov;5(4):351-64 [16302156.001]
  • [Cites] Seizure. 1996 Dec;5(4):291-8 [8952015.001]
  • [Cites] Neuroscience. 2004;129(4):1011-20 [15561416.001]
  • [Cites] Thromb Haemost. 2000 Feb;83(2):209-11 [10739374.001]
  • [Cites] J Intern Med. 1994 Dec;236(6):599-601 [7989895.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):207-13 [15865886.001]
  • [Cites] Thromb Haemost. 1991 Jan 23;65(1):15-9 [1827214.001]
  • [Cites] Am J Med. 1991 Sep;91(3):223-8 [1892141.001]
  • [Cites] J Neurooncol. 1983;1(4):313-7 [6678974.001]
  • [Cites] J Lancet. 1961 Feb;81:46-53 [13703072.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10 ):663-9 [9278462.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12 ):1044-9 [9867760.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1621-4 [3171627.001]
  • [Cites] Neurosurgery. 1985 Mar;16(3):290-2 [2984599.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):593-600 [15627023.001]
  • [Cites] Acta Haematol. 2001;106(1-2):25-32 [11549774.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):119-25 [1331348.001]
  • [Cites] Thromb Haemost. 1998 Jan;79(1):23-7 [9459316.001]
  • [Cites] Am J Med. 2005 Aug;118 Suppl 8A:3S-12S [16125509.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1074-81 [9802851.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):146-53 [12853587.001]
  • [Cites] Surg Neurol. 1981 Dec;16(6):399-401 [7330758.001]
  • [Cites] Mayo Clin Proc. 2004 Dec;79(12):1489-94 [15595331.001]
  • [Cites] Neurology. 1996 Apr;46(4):1029-35 [8780085.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1400-8 [8823305.001]
  • [Cites] Surg Neurol. 2005 Oct;64(4):295-301; discussion 302 [16181995.001]
  • [Cites] Neurocrit Care. 2005;3(3):249-50 [16377838.001]
  • [Cites] Am J Hosp Palliat Care. 2006 Jan-Feb;23(1):35-40 [16450661.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):113-8 [1331347.001]
  • [Cites] Pharmacol Rep. 2005 Jan-Feb;57(1):23-34 [15849374.001]
  • [Cites] Lancet. 1992 Feb 22;339(8791):441-5 [1346817.001]
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2213-20 [14640920.001]
  • [Cites] Neurology. 1988 Feb;38(2):194-8 [3340279.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):268-77 [15254285.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):109-20 [11245271.001]
  • [Cites] J Thromb Thrombolysis. 1999 Aug;8(2):139-42 [10436144.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2522-7 [9667273.001]
  • [Cites] Neurol Clin. 2001 May;19(2):313-45 [11358747.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):41-9 [12125966.001]
  • [Cites] N Engl J Med. 1983 Jul 7;309(1):45-7 [6134237.001]
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):19-33 [7756680.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):652-7 [8636783.001]
  • [Cites] Trends Neurosci. 2001 Dec;24(12):719-25 [11718877.001]
  • [Cites] Ann Neurol. 1989 Jan;25(1):92-4 [2464337.001]
  • [Cites] Onkologie. 2004 Jun;27(3):261-6 [15249715.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1843-53 [16102051.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):49-52 [14765386.001]
  • [Cites] Can J Neurol Sci. 2003 May;30(2):106-12 [12774949.001]
  • [Cites] JAMA. 2001 Nov 21;286(19):2450-60 [11712941.001]
  • [Cites] Neurology. 1993 Jun;43(6):1111-4 [8170553.001]
  • [Cites] Neurology. 1990 Jul;40(7):1144-5 [2356019.001]
  • [Cites] Acta Neurochir (Wien). 1991;109(3-4):93-7 [1858538.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):80-5 [9654538.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):303-20 [15056060.001]
  • [Cites] Arthritis Rheum. 2001 Jul;44(7):1496-503 [11465699.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):299-307 [11981275.001]
  • (PMID = 16807780.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticoagulants; 0 / Anticonvulsants
  • [Number-of-references] 211
  •  go-up   go-down


25. Nishikawa T, Saito J, Omura M: [Medical treatment for Cushing's syndrome]. Nihon Rinsho; 2008 Jan;66(1):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well known that the development of the microvascular disease of various organs such as the heart and kidney, in patients with diabetes mellitus, hyperlipidemia and hypertension of which disorders are frequently associated with Cushing's syndrome.
  • Thus, we should treat Cushing's syndrome as soon as possible, since many complications, including cardiovascular diseases and infections, will soon occur when the definite diagnosis is delayed.
  • Adrenalectomy is essential for treatment for Cushing's syndrome even in the patients with pituitary or ectopic ACTH-producing tumor.
  • Medical adrenalectomy is achieved by using with mitotane which is usually used for adrenocortical cancer.
  • We commonly treat the patients with Cushing's syndrome due to adrenal tumor and pituitary or ectopic ACTH producing tumor by using metyrapone which mainly inhibits 11-hydroxylase.
  • Metyrapone is also recommended to treat the patients who are not well differentiated Cushing's disease from ectopic ACTH syndrome.
  • Replacement therapy with hydrocortisone should be considered if adrenal failure will occur during treatment with those drugs.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186263.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0O54ZQ14I9 / Aminoglutethimide; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; R9400W927I / Ketoconazole; ZS9KD92H6V / Metyrapone
  • [Number-of-references] 6
  •  go-up   go-down


26. Brown JS Jr: Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia. Schizophr Bull; 2009 Jan;35(1):256-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Concurrent with these developments in BPA research, schizophrenia research has continued to find evidence of possible endocrine or neuroendocrine involvement in the disease.
  • [MeSH-major] Brain / anatomy & histology. Brain / physiopathology. Free Radical Scavengers / pharmacology. Hypothalamo-Hypophyseal System / drug effects. Hypothalamo-Hypophyseal System / physiopathology. Phenols / pharmacology. Pituitary-Adrenal System / drug effects. Pituitary-Adrenal System / physiopathology. Schizophrenia / physiopathology

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. Oxytocin .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochem Res. 2002 Oct;27(10):1193-200 [12462417.001]
  • [Cites] Neuropsychopharmacology. 2003 Jan;28(1):1-13 [12496935.001]
  • [Cites] Cell Mol Neurobiol. 2002 Aug;22(4):445-54 [12507393.001]
  • [Cites] Arch Pharm Res. 2002 Dec;25(6):946-53 [12510852.001]
  • [Cites] Biol Psychiatry. 2003 Jan 1;53(1):56-64 [12513945.001]
  • [Cites] Toxicol Sci. 2003 Jan;71(1):74-83 [12520077.001]
  • [Cites] J Neuroendocrinol. 2003 Feb;15(2):134-40 [12535155.001]
  • [Cites] Environ Health Perspect. 2003 Feb;111(2):175-8 [12573901.001]
  • [Cites] Drugs Today (Barc). 2002 Jul;38(7):465-85 [12582464.001]
  • [Cites] Mol Psychiatry. 2003 Feb;8(2):148-55 [12610647.001]
  • [Cites] Neuroscience. 2003;117(3):639-44 [12617968.001]
  • [Cites] Behav Genet. 2001 May;31(3):317-24 [11699604.001]
  • [Cites] Neurobiol Aging. 2001 Nov-Dec;22(6):915-22 [11754999.001]
  • [Cites] Am J Psychiatry. 2001 Jul;158(7):1134-9 [11431236.001]
  • [Cites] J Psychiatry Neurosci. 2002 Jan;27(1):12-27 [11836973.001]
  • [Cites] Am J Med Genet. 2002 Jan 8;114(1):110-5 [11840515.001]
  • [Cites] Biochem Pharmacol. 2002 Mar 15;63(6):1165-76 [11931850.001]
  • [Cites] Biol Psychiatry. 2002 Apr 1;51(7):583-90 [11950460.001]
  • [Cites] Am J Psychiatry. 2002 May;159(5):713-9 [11986121.001]
  • [Cites] Brain Res. 2002 May 24;937(1-2):1-7 [12020856.001]
  • [Cites] Psychopharmacology (Berl). 2002 May;161(3):296-303 [12021833.001]
  • [Cites] Environ Health Perspect. 2002 Jun;110 Suppl 3:397-402 [12060835.001]
  • [Cites] Environ Health Perspect. 2002 Jun;110 Suppl 3:409-14 [12060837.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1052-60 [12065618.001]
  • [Cites] Psychopharmacology (Berl). 2002 Jun;161(4):434-41 [12073172.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Jul 30;137(1):1-12 [12128249.001]
  • [Cites] Mol Psychiatry. 2002;7(6):571-8 [12140780.001]
  • [Cites] Occup Environ Med. 2002 Sep;59(9):625-8 [12205237.001]
  • [Cites] Schizophr Res. 2002 Oct 1;57(2-3):247-58 [12223256.001]
  • [Cites] Neuropsychopharmacology. 2002 Sep;27(3):341-56 [12225692.001]
  • [Cites] Mol Psychiatry. 2002;7(8):837-44 [12232776.001]
  • [Cites] Steroids. 2002 Sep;67(10):859-67 [12231121.001]
  • [Cites] Schizophr Res. 2002 Nov 1;58(1):69-74 [12363392.001]
  • [Cites] FASEB J. 2002 Oct;16(12):1671-3 [12207000.001]
  • [Cites] Reprod Toxicol. 2002 Nov-Dec;16(6):735-9 [12401500.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2839-41 [12407035.001]
  • [Cites] Br J Psychiatry. 2002 Nov;181:363-5 [12411257.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):5185-90 [12414890.001]
  • [Cites] Environ Health Perspect. 2005 Jun;113(6):675-9 [15929888.001]
  • [Cites] J Neurosci. 2005 Jun 1;25(22):5376-81 [15930386.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):239-42 [15939980.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):339-45 [15949229.001]
  • [Cites] J Reprod Dev. 2005 Jun;51(3):315-24 [15738621.001]
  • [Cites] J Neurophysiol. 2005 Sep;94(3):2171-81 [15928052.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Aug;81(4):907-16 [16085296.001]
  • [Cites] J Neurosci. 2005 Aug 24;25(34):7792-800 [16120780.001]
  • [Cites] J Neuroimmunol. 2005 Oct;167(1-2):99-107 [16091293.001]
  • [Cites] Psychopharmacology (Berl). 2005 Aug;180(4):724-34 [15726331.001]
  • [Cites] Neuropsychopharmacology. 2005 Oct;30(10):1883-94 [15798779.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Oct 15;208(2):127-36 [16183386.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD004719 [16235377.001]
  • [Cites] Neurosci Res. 2003 Mar;45(3):345-56 [12631470.001]
  • [Cites] J Neurochem. 2003 Apr;85(1):105-14 [12641732.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):82-9 [12670705.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):395-401 [12676589.001]
  • [Cites] Immunology. 2003 May;109(1):76-86 [12709020.001]
  • [Cites] Arch Gen Psychiatry. 2004 Aug;61(8):774-80 [15289276.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(11):1159-64 [15289160.001]
  • [Cites] Psychoneuroendocrinology. 2004 Nov;29(10):1260-71 [15288705.001]
  • [Cites] Toxicol Sci. 2004 Sep;81(1):139-47 [15166399.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2004 Sep;17(3):112-9 [15312274.001]
  • [Cites] Biol Psychiatry. 2004 Sep 1;56(5):317-22 [15336513.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Sep 17;152(2):177-87 [15351506.001]
  • [Cites] Psychoneuroendocrinology. 2005 Jan;30(1):111-4 [15358449.001]
  • [Cites] Biol Psychiatry. 2004 Sep 15;56(6):427-40 [15364041.001]
  • [Cites] Biochem Pharmacol. 2004 Oct 15;68(8):1631-8 [15451406.001]
  • [Cites] Schizophr Res. 2004 Aug 1;69(2-3):183-8 [15469192.001]
  • [Cites] Psychoneuroendocrinology. 2005 Feb;30(2):212-24 [15471618.001]
  • [Cites] Neuroendocrinology. 2004;80(1):21-30 [15345905.001]
  • [Cites] J Hum Genet. 1999;44(6):428-30 [10570922.001]
  • [Cites] Synapse. 2000 Jan;35(1):39-44 [10579806.001]
  • [Cites] BJU Int. 2000 Jan;85(1):107-13 [10619956.001]
  • [Cites] J Neurosci. 2000 Jan 15;20(2):558-67 [10632585.001]
  • [Cites] Brain Res. 2002 Nov 29;956(2):332-8 [12445703.001]
  • [Cites] Neurosci Lett. 2002 Dec 16;334(3):211-3 [12453631.001]
  • [Cites] J Neurochem. 2003 Dec;87(6):1499-508 [14713305.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):592-603 [14605012.001]
  • [Cites] Neurosci Lett. 2004 Feb 12;356(2):95-8 [14746872.001]
  • [Cites] Psychoneuroendocrinology. 2004 May;29(4):475-85 [14749093.001]
  • [Cites] J Neuroendocrinol. 2004 Feb;16(2):99-104 [14763995.001]
  • [Cites] Psychiatry Res. 2004 Jan 30;125(1):21-8 [14967549.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):60-9 [14969737.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1007:54-63 [14993040.001]
  • [Cites] Neurosci Lett. 2004 Mar 11;357(3):235-7 [15003293.001]
  • [Cites] Acta Psychiatr Scand. 2004 Apr;109(4):269-74 [15008800.001]
  • [Cites] Biol Psychiatry. 2004 Mar 15;55(6):570-7 [15013825.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Apr;309(1):267-74 [14722325.001]
  • [Cites] Life Sci. 2004 Apr 30;74(24):2931-40 [15051418.001]
  • [Cites] Schizophr Res. 2004 Feb 1;66(2-3):97-100 [15061241.001]
  • [Cites] J Neurosci Res. 2004 May 1;76(3):423-33 [15079872.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127B(1):51-9 [15108180.001]
  • [Cites] Hippocampus. 2004;14(3):337-44 [15132433.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jun;286(6):R1024-9 [14988088.001]
  • [Cites] Neurosci Res. 2004 Mar;48(3):345-53 [15154680.001]
  • [Cites] Brain Res. 2004 Jun 25;1012(1-2):66-74 [15158162.001]
  • [Cites] Br J Pharmacol. 2004 Jun;142(3):543-50 [15148266.001]
  • [Cites] Immunology. 2004 Jul;112(3):489-95 [15196218.001]
  • [Cites] Neurosci Lett. 2004 Jul 1;364(2):114-8 [15196690.001]
  • [Cites] Addict Biol. 2004 Mar;9(1):19-25 [15203435.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):424-33 [15212945.001]
  • [Cites] Cell Biol Int. 2004;28(6):463-9 [15223023.001]
  • [Cites] J Neurosci. 2004 Jun 30;24(26):5913-21 [15229239.001]
  • [Cites] J Paediatr Child Health. 2007 Jun;43(6):421-3 [17535169.001]
  • [Cites] Neurosci Lett. 2007 Jun 13;420(2):100-5 [17532137.001]
  • [Cites] Neurosci Res. 2007 Jun;58(2):149-55 [17412439.001]
  • [Cites] Brain Res. 2007 Jul 2;1156:152-67 [17540347.001]
  • [Cites] Int J Neuropsychopharmacol. 2007 Aug;10(4):499-502 [17583597.001]
  • [Cites] J Endocrinol. 2007 Jul;194(1):201-12 [17592034.001]
  • [Cites] J Neural Transm (Vienna). 2007 Jul;114(7):893-8 [17594127.001]
  • [Cites] Cell Mol Life Sci. 2007 Jul;64(13):1609-20 [17453143.001]
  • [Cites] BMC Med Res Methodol. 2007;7:25 [17587444.001]
  • [Cites] J Toxicol Environ Health A. 2007 Aug;70(15-16):1288-95 [17654246.001]
  • [Cites] J Neurosci. 2007 Aug 1;27(31):8278-85 [17670974.001]
  • [Cites] Neuropharmacology. 2007 Aug;53(2):232-41 [17588617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-61 [17670942.001]
  • [Cites] Science. 1980 May 9;208(4444):597-9 [7367881.001]
  • [Cites] Arch Gen Psychiatry. 1983 Jul;40(7):755-61 [6407455.001]
  • [Cites] Physiol Behav. 1983 May;30(5):675-81 [6878473.001]
  • [Cites] Biol Psychiatry. 1985 Nov;20(11):1211-31 [2996642.001]
  • [Cites] J Nerv Ment Dis. 1987 May;175(5):306-8 [3572383.001]
  • [Cites] Neuroscience. 2000;95(2):333-42 [10658612.001]
  • [Cites] J Neuroimmunol. 1999 Dec;100(1-2):156-68 [10695726.001]
  • [Cites] J Neuroendocrinol. 2000 May;12(5):445-52 [10792584.001]
  • [Cites] Arch Gen Psychiatry. 2000 Jul;57(7):685-91 [10891039.001]
  • [Cites] Am J Med Genet. 2000 Jun 12;96(3):373-8 [10898917.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):6862-7 [10995830.001]
  • [Cites] Eur J Pharmacol. 2000 Sep 29;405(1-3):251-61 [11033332.001]
  • [Cites] Psychoneuroendocrinology. 2001 Jan;26(1):27-35 [11070332.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4512-7 [11108262.001]
  • [Cites] FEBS Lett. 2000 Dec 8;486(2):143-8 [11113455.001]
  • [Cites] Neurochem Int. 2001 Feb;38(2):181-86 [11137887.001]
  • [Cites] Brain Res. 2001 Jan 12;888(2):302-305 [11150488.001]
  • [Cites] Mol Psychiatry. 2001 Jan;6(1):112-7 [11244496.001]
  • [Cites] Brain Res. 2001 Mar 16;894(2):167-80 [11251190.001]
  • [Cites] Schizophr Res. 2001 Apr 15;49(1-2):89-98 [11343868.001]
  • [Cites] Neuroendocrinology. 2001 Aug;74(2):77-81 [11474214.001]
  • [Cites] Environ Health Perspect. 2001 Jul;109(7):675-80 [11485865.001]
  • [Cites] Eur J Pharmacol. 2001 Aug 3;425(1):33-41 [11672572.001]
  • [Cites] Arch Gen Psychiatry. 2001 Nov;58(11):1039-46 [11695950.001]
  • [Cites] Biol Psychiatry. 1999 Sep 1;46(5):689-96 [10472421.001]
  • [Cites] Regul Pept. 2004 Dec 15;123(1-3):225-34 [15518916.001]
  • [Cites] Neurotoxicology. 2005 Jan;26(1):17-25 [15527870.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:612-8 [15542770.001]
  • [Cites] Biol Psychiatry. 2004 Dec 1;56(11):844-52 [15576061.001]
  • [Cites] Behav Brain Res. 2005 Jan 30;156(2):251-61 [15582111.001]
  • [Cites] Neuropharmacology. 2005 Jan;48(1):80-92 [15617730.001]
  • [Cites] Regul Pept. 2005 Mar 15;126(1-2):145-53 [15620428.001]
  • [Cites] Life Sci. 2005 Jan 28;76(11):1281-96 [15642598.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):607-12 [15498886.001]
  • [Cites] Schizophr Res. 2005 Mar 1;73(2-3):357-66 [15653282.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):283-90 [15694236.001]
  • [Cites] Schizophr Res. 2005 May 1;74(2-3):125-34 [15721993.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2415-20 [15383462.001]
  • [Cites] Environ Sci. 2004;11(1):1-14 [15746884.001]
  • [Cites] J Neuroimmunol. 2005 Apr;161(1-2):113-22 [15748950.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1737-44 [15618362.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):115-26 [15771705.001]
  • [Cites] Brain Res Bull. 2005 Apr 15;65(3):235-40 [15811586.001]
  • [Cites] Brain Res Bull. 2005 Apr 15;65(3):249-54 [15811588.001]
  • [Cites] Brain Res Bull. 2005 Apr 15;65(3):255-60 [15811589.001]
  • [Cites] Brain Res Bull. 2005 Apr 15;65(3):261-6 [15811590.001]
  • [Cites] Toxicol Sci. 2005 May;85(1):647-56 [15673845.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2005 May 5;135B(1):15-23 [15729733.001]
  • [Cites] Steroids. 2005 Jul;70(8):507-14 [15894034.001]
  • [Cites] Brain Res. 2005 Jun 7;1046(1-2):32-7 [15927548.001]
  • [Cites] Am J Psychiatry. 2005 Jun;162(6):1203-5 [15930071.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Aug;84(4):609-17 [16996120.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(8):2327-34 [17074053.001]
  • [Cites] Life Sci. 2006 Nov 2;79(23):2165-71 [16905155.001]
  • [Cites] Psychopharmacology (Berl). 2006 Dec;189(2):237-47 [17016710.001]
  • [Cites] Neuroscience. 2006 Nov 17;143(1):51-62 [17045750.001]
  • [Cites] Dement Geriatr Cogn Disord. 2006;22(5-6):449-53 [16988505.001]
  • [Cites] J Neurosci Res. 2006 Nov 1;84(6):1197-205 [16902998.001]
  • [Cites] J Psychiatr Res. 2007 Jan-Feb;41(1-2):3-7 [16434055.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):356-62 [16979250.001]
  • [Cites] Toxicol Ind Health. 2006 Sep;22(8):357-62 [17120535.001]
  • [Cites] Neurosci Lett. 2007 Jan 3;411(1):81-5 [17052851.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):486-9 [17108970.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov;1763(11):1229-37 [17055077.001]
  • [Cites] Schizophr Res. 2005 Nov 15;79(2-3):157-73 [16139990.001]
  • [Cites] Toxicol Sci. 2005 Dec;88(2):477-84 [16162846.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5388-96 [16123166.001]
  • [Cites] J Toxicol Environ Health A. 2006 Jan 8;69(1-2):139-58 [16291567.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:27-31 [16273356.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1271-6 [12711627.001]
  • [Cites] Biochem Pharmacol. 2003 Jun 15;65(12):2049-54 [12787885.001]
  • [Cites] Br J Pharmacol. 2003 Jun;139(3):495-500 [12788809.001]
  • [Cites] Biol Psychiatry. 2003 Jun 15;53(12):1086-98 [12814860.001]
  • [Cites] Environ Res. 2003 Sep;93(1):31-5 [12865045.001]
  • [Cites] Neuropsychopharmacology. 2003 Aug;28(8):1515-20 [12799618.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):486-92 [12967774.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4466-77 [12960093.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4734-8 [12960039.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2003 Nov 15;123B(1):33-8 [14582143.001]
  • [Cites] Eur Psychiatry. 2003 Oct;18(6):274-81 [14611921.001]
  • [Cites] Neuroscience. 2003;122(3):757-72 [14622919.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):877-82 [14651953.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):551-61 [14664715.001]
  • [Cites] Neurosci Lett. 2003 Dec 19;353(2):99-102 [14664910.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51654-63 [14534309.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):191-4 [14687873.001]
  • [Cites] J UOEH. 2003 Dec 1;25(4):365-74 [14692339.001]
  • [Cites] Am J Psychiatry. 2004 Jan;161(1):109-15 [14702258.001]
  • [Cites] Behav Brain Res. 2006 Mar 15;168(1):150-60 [16387372.001]
  • [Cites] Curr Pharm Des. 2006;12(1):93-109 [16454728.001]
  • [Cites] Neurotoxicol Teratol. 2006 Jan-Feb;28(1):111-8 [16427766.001]
  • [Cites] J Pediatr Surg. 2006 Mar;41(3):463-72 [16516617.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):70-80 [16537998.001]
  • [Cites] Psychiatr Genet. 2006 Apr;16(2):73-6 [16538184.001]
  • [Cites] BMC Immunol. 2006;7:2 [16504066.001]
  • [Cites] Neuropsychopharmacology. 2006 Apr;31(4):885-9 [16237386.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):72-6 [16091861.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):77-81 [16133738.001]
  • [Cites] Mol Psychiatry. 2006 May;11(5):514-22 [16415915.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12673-81 [16524877.001]
  • [Cites] Neurotoxicology. 2007 Jan;28(1):1-12 [17109964.001]
  • [Cites] Neurotoxicol Teratol. 2007 Jan-Feb;29(1):108-15 [17157476.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):361-4 [17081670.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):378-82 [17110010.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:8 [17274816.001]
  • [Cites] J Neurochem. 2007 Mar;100(5):1375-86 [17254027.001]
  • [Cites] Pharmacol Biochem Behav. 2007 Jan;86(1):8-20 [17257664.001]
  • [Cites] Brain Res. 2007 Mar 30;1139:1-5 [17270153.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(3):805-11 [17019564.001]
  • [Cites] Schizophr Res. 2007 Mar;91(1-3):51-61 [17270400.001]
  • [Cites] Schizophr Res. 2007 Mar;91(1-3):1-5 [17306505.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2007 Feb;17(1):105-14 [17343558.001]
  • [Cites] Int Rev Neurobiol. 2007;78:377-95 [17349867.001]
  • [Cites] Chemosphere. 2007 Apr;67(9):S412-20 [17223178.001]
  • [Cites] Chemosphere. 2007 Apr;67(9):S405-11 [17254629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2815-20 [17360599.001]
  • [Cites] J Prev Med Public Health. 2007 Mar;40(2):155-61 [17426428.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2007 Apr;257(3):135-9 [17131219.001]
  • [Cites] Neuropsychopharmacology. 2007 May;32(5):1178-94 [16985504.001]
  • [Cites] Neuropsychopharmacology. 2007 May;32(5):1133-40 [17019405.001]
  • [Cites] J Pineal Res. 2007 Apr;42(4):403-10 [17439557.001]
  • [Cites] Brain Res. 2007 May 29;1149:50-7 [17382304.001]
  • [Cites] Cell Biol Int. 2007 Jun;31(6):638-44 [17210262.001]
  • [Cites] Brain Dev. 2007 Jul;29(6):352-6 [17113258.001]
  • [Cites] Neurosci Lett. 2007 May 18;418(3):236-41 [17467901.001]
  • [Cites] Neuropsychopharmacology. 2007 Jun;32(6):1251-60 [17119541.001]
  • [Cites] Nihon Shinkei Seishin Yakurigaku Zasshi. 2007 Apr;27(2):69-75 [17515113.001]
  • [Cites] Neurobiol Dis. 2007 Jun;26(3):634-45 [17459716.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1771(8):1031-45 [17569578.001]
  • [Cites] Psychiatry Res. 2007 Aug 30;152(2-3):173-80 [17448544.001]
  • [Cites] Toxicol Lett. 2007 Aug 30;173(1):66-72 [17689037.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4344-51 [17569755.001]
  • [Cites] J Neurosci. 2007 Aug 15;27(33):8816-25 [17699663.001]
  • [Cites] Schizophr Bull. 1988;14(2):231-41 [3059470.001]
  • [Cites] Br J Psychiatry. 1989 Dec;155:857-9 [2515912.001]
  • [Cites] Schizophr Bull. 1990;16(4):591-604 [2077637.001]
  • [Cites] Brain Res Mol Brain Res. 1991 Sep;11(2):125-32 [1661809.001]
  • [Cites] Genomics. 1991 Dec;11(4):1113-24 [1838348.001]
  • [Cites] Schizophr Bull. 1992;18(2):159-70 [1621064.001]
  • [Cites] J Neurochem. 1994 Sep;63(3):980-7 [7519668.001]
  • [Cites] Toxicology. 1994 Nov-Dec;94(1-3):19-30 [7801322.001]
  • [Cites] FEBS Lett. 1996 Mar 4;381(3):257-61 [8601467.001]
  • [Cites] J Mol Neurosci. 1995;6(2):141-6 [8746452.001]
  • [Cites] Synapse. 1997 Jan;25(1):80-92 [8987151.001]
  • [Cites] Psychiatry Clin Neurosci. 1997 Apr;51(2):83-5 [9141146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7240-4 [9636132.001]
  • [Cites] Psychiatr Clin North Am. 1998 Jun;21(2):413-34 [9670234.001]
  • [Cites] Am J Psychiatry. 1998 Sep;155(9):1288-90 [9734558.001]
  • [Cites] Hum Reprod Update. 1998 Jul-Aug;4(4):406-19 [9825855.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jan 22;64(1):119-31 [9889345.001]
  • [Cites] Brain Res. 1999 Mar 20;822(1-2):200-9 [10082897.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Jun;221(2):131-5 [10352124.001]
  • [Cites] Neuropsychopharmacology. 2007 Jan;32(1):95-102 [16641945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19338-43 [17159139.001]
  • [Cites] Trends Neurosci. 2007 Jan;30(1):22-30 [17134767.001]
  • [Cites] Reprod Toxicol. 2007 Jan;23(1):42-54 [17011747.001]
  • [Cites] Mol Med. 2006 Sep-Oct;12(9-10):237-45 [17225872.001]
  • [Cites] J Neurochem. 2007 Feb;100(3):780-9 [17263796.001]
  • [Cites] J Neuroendocrinol. 2006 Jun;18(6):434-44 [16684133.001]
  • [Cites] Horm Behav. 2007 Sep;52(3):307-16 [17568585.001]
  • [Cites] Neurosci Res. 2007 Sep;59(1):8-17 [17574696.001]
  • [Cites] J Psychiatr Res. 2007 Dec;41(12):1042-6 [17049557.001]
  • [Cites] PLoS One. 2007;2(8):e809 [17726539.001]
  • [Cites] J Toxicol Sci. 2007 Aug;32(3):301-10 [17785945.001]
  • [Cites] Psychol Med. 2007 Oct;37(10):1427-36 [17451629.001]
  • [Cites] Reprod Toxicol. 2007 Aug-Sep;24(2):131-8 [17768031.001]
  • [Cites] Pharmacol Ther. 2007 Oct;116(1):1-6 [17531324.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7):849-53 [17503482.001]
  • [Cites] Biosci Biotechnol Biochem. 2007 Sep;71(9):2136-43 [17827700.001]
  • [Cites] Neurol Res. 2007 Sep;29(6):622-7 [17535560.001]
  • [Cites] J Neurosci. 2007 Oct 3;27(40):10695-702 [17913903.001]
  • [Cites] Schizophr Res. 2007 Nov;96(1-3):246-56 [17719205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6 [17921251.001]
  • [Cites] J Psychiatr Res. 2008 Jan;42(2):125-33 [17140601.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):407-15 [17784851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18736-41 [18003893.001]
  • [Cites] Schizophr Bull. 2008 Jan;34(1):155-72 [17562694.001]
  • [Cites] Psychol Med. 2008 Jan;38(1):71-7 [17662165.001]
  • [Cites] Toxicol In Vitro. 2008 Feb;22(1):1-9 [17761398.001]
  • [Cites] Mol Psychiatry. 2008 Feb;13(2):147-61 [17471287.001]
  • [Cites] Biol Psychiatry. 2008 Mar 1;63(5):530-3 [17870056.001]
  • [Cites] Brain Res Rev. 2008 Mar;57(2):352-62 [17822772.001]
  • [Cites] Neurosci Res. 2007 Feb;57(2):248-58 [17141345.001]
  • [Cites] J Neurochem. 2006 Jun;97(5):1243-58 [16524369.001]
  • [Cites] Endocrinology. 2006 Jun;147(6):2773-80 [16543366.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S43-9 [16690803.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S4-10 [16690812.001]
  • [Cites] Neuropsychopharmacology. 2006 Jun;31(6):1249-63 [16319920.001]
  • [Cites] Maturitas. 2006 Jun 20;54(3):238-44 [16406399.001]
  • [Cites] Brain Res Rev. 2006 Jun;51(1):61-71 [16325258.001]
  • [Cites] Neuroscience. 2006 Aug 11;141(1):379-89 [16675138.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):700-8 [16699066.001]
  • [Cites] Endocrinology. 2006 Aug;147(8):3681-91 [16675520.001]
  • [Cites] Immunol Res. 2006;34(3):177-92 [16891670.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Jul;37(4):570-3 [16909604.001]
  • [Cites] Neuropsychobiology. 2006;53(4):169-75 [16763376.001]
  • [Cites] Schizophr Res. 2006 Sep;86(1-3):118-22 [16806835.001]
  • [Cites] Toxicology. 2006 Sep 21;226(2-3):131-42 [16860915.001]
  • [Cites] Toxicology. 2006 Sep 21;226(2-3):79-89 [16860916.001]
  • [Cites] Horm Behav. 2006 Nov;50(4):612-22 [16876167.001]
  • [Cites] J Neuroimmunol. 2006 Sep;178(1-2):76-86 [16844232.001]
  • [Cites] Schizophr Res. 2006 Oct;87(1-3):6-14 [16797925.001]
  • [Cites] Am J Psychiatry. 2006 Oct;163(10):1829-31 [17012697.001]
  • [Cites] Hum Mol Genet. 2006 Nov 1;15(21):3132-45 [16984965.001]
  • [Cites] J Autoimmun. 2006 Sep;27(2):71-80 [16997531.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):702-13 [17096328.001]
  • [Cites] Neuroendocrinology. 2006;83(5-6):348-59 [16931878.001]
  • [Cites] Food Chem Toxicol. 2007 Feb;45(2):202-9 [17011104.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):97-104 [16648781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19164-9 [17146058.001]
  • [Cites] Biol Psychiatry. 2005 Nov 15;58(10):812-24 [16112656.001]
  • [Cites] Brain Res. 2005 Dec 7;1064(1-2):10-20 [16298349.001]
  • [Cites] Dis Markers. 2006;22(1-2):83-93 [16410648.001]
  • [Cites] Neuroscience. 2006 Feb;137(3):807-19 [16330153.001]
  • [Cites] Neurobiol Dis. 2006 Feb;21(2):413-20 [16246567.001]
  • [Cites] Eur Neuropsychopharmacol. 2006 Feb;16(2):137-46 [16139994.001]
  • (PMID = 18245062.001).
  • [ISSN] 0586-7614
  • [Journal-full-title] Schizophrenia bulletin
  • [ISO-abbreviation] Schizophr Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Estrogens; 0 / Free Radical Scavengers; 0 / Phenols; 4G7DS2Q64Y / Progesterone; 50-56-6 / Oxytocin; MLT3645I99 / bisphenol A
  • [Number-of-references] 334
  • [Other-IDs] NLM/ PMC2643957
  •  go-up   go-down


27. McMullen MH, Hamilton-Reeves JM, Bonorden MJ, Wangen KE, Phipps WR, Feirtag JM, Kurzer MS: Consumption of Lactobacillus acidophilus and Bifidobacterium longum does not alter phytoestrogen metabolism and plasma hormones in men: a pilot study. J Altern Complement Med; 2006 Nov;12(9):887-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to determine whether equol excretion status and plasma hormone and leptin concentrations can be influenced by consumption of a probiotic supplement.
  • A secondary focus was to investigate whether male equol excretors have a hormone profile consistent with reduced prostate cancer risk.
  • A secondary finding was that male equol excretors in this study did not exhibit a hormone profile consistent with reduced prostate cancer risk, although this result should be interpreted with caution.
  • [MeSH-major] Adrenal Cortex Hormones / blood. Bifidobacterium. Lactobacillus acidophilus. Phytoestrogens / metabolism. Probiotics / administration & dosage

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109580.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00400
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4',7-dihydroxy-3,4-dihydroisoflavone; 0 / Adrenal Cortex Hormones; 0 / Hormones; 0 / Isoflavones; 0 / Leptin; 0 / Phytoestrogens; 0 / Sex Hormone-Binding Globulin; 08J2K08A3Y / Dihydrotestosterone; 21255-69-6 / O-desmethylangolensin; 25126-76-5 / Androstane-3,17-diol; 27195-25-1 / androstane-3,17-diol glucuronide; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; 531-95-3 / Equol; 57B09Q7FJR / Dehydroepiandrosterone Sulfate; 6287WC5J2L / daidzein; 92M5F28TVF / glycitein; DH2M523P0H / Genistein
  •  go-up   go-down


28. Fujiwara M, Imachi H, Murao K, Muraoka T, Ohyama T, Miyai Y, Kushida Y, Haba R, Kakehi Y, Ishida T: Improvement in renal dysfunction and symptoms after laparoscopic adrenalectomy in a patient with pheochromocytoma complicated by renal dysfunction. Endocrine; 2009 Feb;35(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in renal dysfunction and symptoms after laparoscopic adrenalectomy in a patient with pheochromocytoma complicated by renal dysfunction.
  • A 70-year-old patient who was undergoing treatment for diabetes mellitus and chronic hepatitis was admitted to our hospital for evaluation of a tumor in the left adrenal gland (50 x 45 mm) and renal failure.
  • On the basis of the patient's increased serum concentrations of catecholamines and other metabolites and the results of positron emission tomography (PET), the patient was diagnosed with a pheochromocytoma; iodinated metaiodobenzylguanidine ([(131)I]MIBG) scintigraphy was insufficient to establish this diagnosis.
  • Subsequently, he underwent surgery for tumor resection.
  • Histological examination suggested the tumor to be a malignant pheochromocytoma.
  • Furthermore, his renal function improved (Cr 2.0-1.2 mg/dl).
  • Our patient exhibited a rare condition of pheochromocytoma complicated by renal failure, which was successfully treated with laparoscopic surgery.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy. Pheochromocytoma / surgery. Renal Insufficiency / surgery


29. Corcione F, Miranda L, Marzano E, Capasso P, Cuccurullo D, Settembre A, Pirozzi F: Laparoscopic adrenalectomy for malignant neoplasm: our experience in 15 cases. Surg Endosc; 2005 Jun;19(6):841-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic adrenalectomy for malignant neoplasm: our experience in 15 cases.
  • BACKGROUND: We report our experience with laparoscopic adrenalectomy (LA) for malignant pathologies that in some cases required a multiorgan resection.
  • METHODS: In this study, we retrospectively reviewed a group of 15 patients (10 men, and five women) who underwent an operation for primitive or metastatic adrenal malignant tumors.
  • Six patients, with a follow-up ranging from 3 to 24 months (mean 13.6 months), are disease free; the others developed metastatic repetitions or local recurrences.
  • CONCLUSIONS: LA could be performed always respecting the oncological principles of radical excisions.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):749-64 [9735132.001]
  • [Cites] Surgery. 2002 Dec;132(6):1064-8; discussion 1068-9 [12490856.001]
  • [Cites] Surgery. 1996 Oct;120(4):706-9; discussion 710-1 [8862381.001]
  • [Cites] World J Surg. 1999 Apr;23(4):389-96 [10030863.001]
  • [Cites] Am J Hematol. 1988 Mar;27(3):228-9 [3348209.001]
  • [Cites] J Endourol. 2000 Mar;14 (2):149-54 [10772507.001]
  • [Cites] Surgery. 1997 Dec;122(6):1132-6 [9426429.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):149-54 [7898109.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Mar;22(1):141-5 [12725334.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] World J Surg. 2003 Feb;27(2):223-8 [12616441.001]
  • [Cites] Ann Thorac Surg. 1996 Dec;62(6):1614-6 [8957360.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] Br J Surg. 2002 Jun;89(6):779-82 [12027991.001]
  • [Cites] Ann Chir. 2002 Sep;127(7):512-9 [12404845.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):480-5 [12052760.001]
  • (PMID = 15868253.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Plouin PF, Gimenez-Roqueplo AP: Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis; 2006;1:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in extraadrenal chromaffin cells (secreting paragangliomas).
  • Their prevalence is about 0.1% in patients with hypertension and 4% in patients with a fortuitously discovered adrenal mass.
  • These tumors may be sporadic or part of any of several genetic diseases: familial pheochromocytoma-paraganglioma syndromes, multiple endocrine neoplasia type 2, neurofibromatosis 1 and von Hippel-Lindau disease.
  • The most specific and sensitive diagnostic test for the tumor is the determination of plasma or urinary metanephrines.
  • The tumor can be located by computed tomography, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy.
  • Treatment requires resection of the tumor, generally by laparoscopic surgery.
  • About 10% of tumors are malignant either at first operation or during follow-up, malignancy being diagnosed by the presence of lymph node, visceral or bone metastases.
  • Recurrences and malignancy are more frequent in cases with large or extraadrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / secretion. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Adrenal Gland Diseases / diagnosis. Catecholamines / biosynthesis. Catecholamines / secretion. Diagnosis, Differential. Genetic Testing / methods. Humans. Hypertension / etiology. Prognosis. Proto-Oncogene Proteins c-ret / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4533-9 [14557417.001]
  • [Cites] Trends Endocrinol Metab. 2003 Dec;14(10):453-9 [14643060.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):197-211 [15013219.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Medicine (Baltimore). 1991 Jan;70(1):33-45 [1988765.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2503-9 [7593641.001]
  • [Cites] Ann Intern Med. 1996 Aug 15;125(4):300-3 [8678394.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4771-4 [12364472.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6 [15644401.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8812-8 [16314641.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):60-1 [16932255.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1235-46 [12368197.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6 [11297571.001]
  • [Cites] Am J Hum Genet. 2001 Dec;69(6):1186-97 [11605159.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Eur J Endocrinol. 2002 Jul;147(1):85-94 [12088924.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66 [12788870.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:41-53 [12381540.001]
  • [Cites] Hypertension. 1997 May;29(5):1133-9 [9149678.001]
  • (PMID = 17156452.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  • [Number-of-references] 29
  • [Other-IDs] NLM/ PMC1702343
  • [General-notes] NLM/ Original DateCompleted: 20070718
  •  go-up   go-down


31. Dreijerink KM, Lips CJ: Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1). Hered Cancer Clin Pract; 2005;3(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1).
  • Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited disorder, characterised by the occurrence of tumours of the parathyroid glands, the pancreatic islets, the pituitary gland, the adrenal glands and neuroendocrine carcinoid tumours.
  • Carcinoid tumours of the thymus and pancreatic-duodenal gastrinomas are the most harmful tumour types, since these tumours have malignant potential and curative treatment is difficult to achieve.MEN1 is caused by germline mutations of the MEN1 tumour suppressor gene.
  • MEN1 patients and their family members, family members of mutation carriers and patients who are clinically suspected to be carriers of a MEN1 gene mutation are eligible for mutation analysis.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Surgery. 1998 Dec;124(6):1106-13; discussion 1113-4 [9854591.001]
  • [Cites] Cell. 1999 Jan 8;96(1):143-52 [9989505.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):51-6 [10500243.001]
  • [Cites] Eur J Clin Invest. 2000 Jun;30(6):487-92 [10849016.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4776-80 [11134142.001]
  • [Cites] Radiology. 2001 Sep;220(3):631-9 [11526260.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4917-25 [11526476.001]
  • [Cites] Ned Tijdschr Geneeskd. 2002 Sep 14;146(37):1735-9 [12357875.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1066-81 [12629087.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 May;58(5):639-46 [12699448.001]
  • [Cites] Cell. 2003 Jun 27;113(7):881-9 [12837246.001]
  • [Cites] Eur J Endocrinol. 2003 Dec;149(6):577-82 [14641000.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):587-97 [14992727.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] QJM. 1996 Sep;89(9):653-69 [8917740.001]
  • [Cites] Hum Mutat. 1998;11(4):264-9 [9554741.001]
  • (PMID = 20223025.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2837063
  •  go-up   go-down


32. Horinouchi H, Yamao S, Gotoh S, Jinta T, Nishimura N, Suzuki K, Chohnabayashi N: [Two cases of invasive pulmonary aspergillosis mimicking pneumonia in lung cancer patients]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):786-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of invasive pulmonary aspergillosis mimicking pneumonia in lung cancer patients].
  • BACKGROUND: Invasive pulmonary aspergillosis (IPA) occurs predominantly in immunocompromised hosts, however increasing numbers of cases of IPA have been reported among basically immunocompetent patients who have some pulmonary abnormalities such as lung cancer and chronic obstructive pulmonary disease (COPD).
  • He had COPD and small cell lung cancer and had finished chemotherapy 5 years previously.
  • He had COPD and non-small cell lung cancer and finished chemotherapy 2 months previously.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Immunocompromised Host. Invasive Pulmonary Aspergillosis / diagnosis. Invasive Pulmonary Aspergillosis / etiology. Lung Neoplasms / complications. Small Cell Lung Carcinoma / complications
  • [MeSH-minor] Adrenal Cortex Hormones / adverse effects. Aged. Aged, 80 and over. Antifungal Agents. Community-Acquired Infections. Diagnosis, Differential. Fatal Outcome. Humans. Male. Pneumonia, Bacterial. Pulmonary Disease, Chronic Obstructive / complications. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827582.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antifungal Agents
  •  go-up   go-down


33. Slatcher RB, Robles TF, Repetti RL, Fellows MD: Momentary work worries, marital disclosure, and salivary cortisol among parents of young children. Psychosom Med; 2010 Nov;72(9):887-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, they suggest that, for women, the stress-buffering effects of a happy marriage may be partially explained by the extent to which they disclose their thoughts and feelings with their spouses.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:33-44 [9629234.001]
  • [Cites] Psychol Bull. 1992 Jul;112(1):155-9 [19565683.001]
  • [Cites] Health Psychol. 1998 Nov;17(6):537-45 [9848804.001]
  • [Cites] Adv Mind Body Med. 1999 Summer;15(3):184-93 [10446474.001]
  • [Cites] J Fam Psychol. 2004 Dec;18(4):589-99 [15598164.001]
  • [Cites] J Fam Psychol. 2005 Mar;19(1):86-97 [15796655.001]
  • [Cites] Psychoneuroendocrinology. 2005 Aug;30(7):647-56 [15854781.001]
  • [Cites] Psychoneuroendocrinology. 2005 Aug;30(7):698-714 [15854786.001]
  • [Cites] J Fam Psychol. 2005 Jun;19(2):314-23 [15982109.001]
  • [Cites] Psychol Sci. 2006 Aug;17(8):660-4 [16913946.001]
  • [Cites] Psychosom Med. 2006 Sep-Oct;68(5):742-6 [16987948.001]
  • [Cites] Psychol Bull. 2006 Nov;132(6):823-65 [17073523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):17058-63 [17075058.001]
  • [Cites] J Fam Psychol. 2006 Dec;20(4):690-700 [17176205.001]
  • [Cites] Psychoneuroendocrinology. 2007 Jan;32(1):56-64 [17157442.001]
  • [Cites] Br J Health Psychol. 2008 Feb;13(Pt 1):85-93 [18230238.001]
  • [Cites] Health Psychol. 2008 Jan;27(1):15-25 [18230009.001]
  • [Cites] J Appl Psychol. 2008 Mar;93(2):443-52 [18361643.001]
  • [Cites] J Pers Soc Psychol. 2010 Jan;98(1):92-103 [20053034.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000 [10861311.001]
  • [Cites] Psychol Bull. 2001 Jul;127(4):472-503 [11439708.001]
  • [Cites] Psychosom Med. 2003 Mar-Apr;65(2):313-9 [12652000.001]
  • [Cites] Physiol Behav. 2003 Aug;79(3):409-16 [12954435.001]
  • [Cites] Psychoneuroendocrinology. 2004 May;29(4):516-28 [14749096.001]
  • [Cites] J Fam Psychol. 2004 Mar;18(1):250-63 [14992625.001]
  • [Cites] Psychosom Med. 2004 Mar-Apr;66(2):207-14 [15039505.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] J Nerv Ment Dis. 1987 Sep;175(9):526-36 [3655778.001]
  • [Cites] Neuropsychobiology. 1989;22(3):150-69 [2485862.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Dec;43(7):683-92 [1472460.001]
  • [Cites] Circulation. 1994 Jul;90(1):87-93 [8026056.001]
  • [Cites] Psychoneuroendocrinology. 1994;19(4):313-33 [8047637.001]
  • [Cites] Psychosom Med. 1996 Sep-Oct;58(5):447-58 [8902896.001]
  • [Cites] Psychosom Med. 2008 Oct;70(8):883-9 [18842747.001]
  • [Cites] Biol Psychol. 2009 Mar;80(3):265-78 [19022335.001]
  • [Cites] Psychother Psychosom. 2009;78(3):145-51 [19270469.001]
  • [Cites] Psychoneuroendocrinology. 1998 May;23(4):353-70 [9695136.001]
  • (PMID = 20841560.001).
  • [ISSN] 1534-7796
  • [Journal-full-title] Psychosomatic medicine
  • [ISO-abbreviation] Psychosom Med
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH052391; United States / NIMH NIH HHS / MH / T32 MH015750; United States / NIMH NIH HHS / MH / MH015750; United States / NIMH NIH HHS / MH / MH52391
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ NIHMS237358; NLM/ PMC2978267
  •  go-up   go-down


34. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB: Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood; 2009 Nov 26;114(23):4777-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighteen (45%) children developed ICH within 7 days of diagnosis of ITP; for 10 of these, ICH was the presenting feature of ITP.

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 Feb 2;371(9610):395-403 [18242413.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):16-26 [18573111.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4003-8 [18698007.001]
  • [Cites] Pediatr Blood Cancer. 2009 Apr;52(4):529-31 [19058201.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2386-93 [19005182.001]
  • [Cites] J Pediatr. 2000 Nov;137(5):629-32 [11060527.001]
  • [Cites] Ann Hematol. 2000 Dec;79(12):691-5 [11195007.001]
  • [Cites] J Pediatr. 2001 May;138(5):787-8 [11343071.001]
  • [Cites] Semin Thromb Hemost. 2001 Jun;27(3):253-67 [11446659.001]
  • [Cites] Indian Pediatr. 2002 May;39(5):468-72 [12037279.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):660-4 [12902925.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Dec;25 Suppl 1:S74-6 [14668646.001]
  • [Cites] Pediatrics. 1981 Apr;67(4):570-1 [7196013.001]
  • [Cites] Eur J Pediatr. 1987 Mar;146(2):107-12 [3552690.001]
  • [Cites] N Engl J Med. 1993 Apr 29;328(17):1226-9 [8464433.001]
  • [Cites] Arch Dis Child. 1994 Sep;71(3):251-3 [7979501.001]
  • [Cites] Blood. 1996 Jul 1;88(1):3-40 [8704187.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1465; author reply 1466 [9028974.001]
  • [Cites] Neurology. 1998 Apr;50(4):1160-3 [9566417.001]
  • [Cites] J Pediatr. 1998 Sep;133(3):334-9 [9738712.001]
  • [Cites] Semin Thromb Hemost. 1998;24(6):545-8 [10066149.001]
  • [Cites] Acta Paediatr. 2005 Feb;94(2):178-84 [15981751.001]
  • [Cites] J Pediatr. 2006 Apr;148(4):489-94 [16647411.001]
  • [Cites] N Engl J Med. 2006 Oct 19;355(16):1672-81 [17050891.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):245-8 [17542983.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):515-9 [17934361.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):526-34 [17934363.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3526-31 [17698634.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2237-47 [18046028.001]
  • [Cites] Curr Opin Pediatr. 2008 Feb;20(1):8-16 [18197033.001]
  • [CommentIn] Blood. 2009 Nov 26;114(23):4758-9 [19965695.001]
  • (PMID = 19767509.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NHLBI NIH HHS / HL / U01 HL072186; United States / NCRR NIH HHS / RR / UL1RR024996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Other-IDs] NLM/ PMC2786288
  •  go-up   go-down


35. Louiset E, Stratakis CA, Perraudin V, Griffin KJ, Libé R, Cabrol S, Fève B, Young J, Groussin L, Bertherat J, Lefebvre H: The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. J Clin Endocrinol Metab; 2009 Jul;94(7):2406-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits.
  • CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) results in most cases from mutations of the protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene.

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11893-8 [11027313.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2085-91 [19293268.001]
  • [Cites] Am J Hum Genet. 2002 Dec;71(6):1433-42 [12424709.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3931-7 [12915689.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5308-19 [14500362.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):265-80 [15163302.001]
  • [Cites] Biochim Biophys Acta. 1983 Aug 17;763(1):83-9 [6307394.001]
  • [Cites] Neuroscience. 1992;47(4):999-1007 [1374544.001]
  • [Cites] Biochim Biophys Acta. 1996 Dec 11;1309(3):211-20 [8982258.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):47-54 [9435415.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):348-52 [9467539.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):456-63 [9694579.001]
  • [Cites] Ann Intern Med. 1999 Oct 19;131(8):585-91 [10523219.001]
  • [Cites] J Med Genet. 2004 Dec;41(12):923-31 [15591278.001]
  • [Cites] Mol Cell Endocrinol. 2006 Feb 26;246(1-2):142-6 [16388891.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1943-9 [16464939.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4578-86 [16954157.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):748-57 [17955016.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):4016-24 [18559625.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1108-15 [19139432.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • (PMID = 19383776.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000642; United States / NICHD NIH HHS / HD / Z01-HD-000642-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NR3C1 protein, human; 0 / Receptors, Glucocorticoid; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2708955
  •  go-up   go-down


36. Bisenkov LN, Shalaev SA, Orzheshkovskiĭ OV, Platunov SK, Efremov FA: [One-stage operations on the lungs and other organs in multifocal and metastatic cancer]. Khirurgiia (Mosk); 2005;(4):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One-stage operations on the lungs and other organs in multifocal and metastatic cancer].
  • Surgical treatment of 135 patients with multifocal and metastatic cancer of the lungs and other organs is analyzed.
  • The absence of absolute differential diagnostic differences between true poly-neoplasia and synchronous or metachronous solitary metastases leads to extension of indications to surgical treatment of these patients.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Digestive System Neoplasms / surgery. Kidney Neoplasms / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Diagnosis, Differential. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / surgery. Esophagoplasty. Gastrectomy. Humans. Length of Stay. Nephrectomy. Pneumonectomy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery. Time Factors


37. Westerlund M, Belin AC, Olson L, Galter D: Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res; 2008 Nov;334(2):179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The membrane transporter multi-drug resistance 1 (MDR1, P-gp) regulates the bioavailability of endogenous and exogenous compounds and has been implicated in disorders such as Parkinson's disease, cancer, epilepsy, human immunodeficiency virus disease, and inflammatory bowel disease.
  • To promote further understanding of the role of MDR1 in disease, we have characterized cellular MDR1 mRNA expression in post-mortem human and fresh-frozen Sprague-Dawley rat tissues by using radioactive oligonucleotide probe in situ hybridization.
  • In peripheral tissues, we have observed MDR1 mRNA in human and rat liver and renal tubules and in human adrenal cortex and the epithelial lining of rat intestine.
  • [MeSH-major] P-Glycoprotein / metabolism. Parkinson Disease / metabolism

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855017.001).
  • [ISSN] 1432-0878
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Messenger
  •  go-up   go-down


38. Kosir R, Acimovic J, Golicnik M, Perse M, Majdic G, Fink M, Rozman D: Determination of reference genes for circadian studies in different tissues and mouse strains. BMC Mol Biol; 2010;11:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their disruption can lead to serious pathologies, such as cancer and obesity.
  • RESULTS: In the present study the expression of ten candidate reference genes (Actb, Eif2a, Gapdh, Hmbs, Hprt1, Ppib, Rn18s, Rplp0, Tbcc and Utp6c) was measured in 131 liver and 97 adrenal gland samples taken from three mouse strains (C57BL/6JOlaHsd, 129Pas plus C57BL/6J and Crem KO on 129Pas plus C57BL/6J background) every 4 h in a 24 h period.
  • We show that the use of a single reference gene can lead to false biological conclusions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2006;6:200 [16872493.001]
  • [Cites] Anal Biochem. 2010 Jun 1;401(1):81-90 [20153286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16364-9 [17053075.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:593-628 [17209800.001]
  • [Cites] Neurosci Res. 2007 Apr;57(4):483-90 [17303272.001]
  • [Cites] PLoS Genet. 2008 Feb;4(2):e1000023 [18454201.001]
  • [Cites] Biotechniques. 2008 Apr;44(5):619-26 [18474036.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1197-204 [18418054.001]
  • [Cites] BMC Mol Biol. 2008;9:53 [18505597.001]
  • [Cites] Cell. 2008 Jul 25;134(2):317-28 [18662546.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 12;374(1):106-10 [18602371.001]
  • [Cites] J Am Soc Nephrol. 2000 Nov;11 Suppl 16:S101-5 [11065339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2707-11 [11226304.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):935-41 [12198538.001]
  • [Cites] J Mol Endocrinol. 2002 Aug;29(1):23-39 [12200227.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 25;298(2):198-202 [12387815.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9 [15283208.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2004;5:407-41 [15485355.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1257-66 [2261643.001]
  • [Cites] Science. 1994 Apr 29;264(5159):719-25 [8171325.001]
  • [Cites] EMBO J. 1997 Nov 17;16(22):6762-71 [9362490.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e377 [15523558.001]
  • [Cites] Science. 2005 May 13;308(5724):1043-5 [15845877.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Mol Endocrinol. 2005 Jun;34(3):597-601 [15956331.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):493-8 [16013967.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):306-12 [16182241.001]
  • [Cites] ILAR J. 2006;47(2):94-102 [16547366.001]
  • [Cites] PLoS Comput Biol. 2006 Mar;2(3):e16 [16532060.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1715-27 [16556735.001]
  • [Cites] Cell. 2008 Sep 5;134(5):728-42 [18775307.001]
  • [Cites] Nat Rev Genet. 2008 Oct;9(10):764-75 [18802415.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1779(12):830-7 [18790095.001]
  • [Cites] BMC Bioinformatics. 2009;10:42 [19187545.001]
  • [Cites] Nat Rev Cancer. 2009 Dec;9(12):886-96 [19935677.001]
  • [Cites] J Appl Physiol (1985). 2009 Dec;107(6):1959-64 [19574505.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2010;50:377-421 [20055686.001]
  • [Cites] BMC Mol Biol. 2009;10:106 [20003366.001]
  • [Cites] BMC Mol Biol. 2010;11:7 [20089183.001]
  • [Cites] BMC Mol Biol. 2010;11:15 [20156357.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R271-7 [16987893.001]
  • (PMID = 20712867.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2928770
  •  go-up   go-down


39. Fekete C, Lechan RM: Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase. Front Neuroendocrinol; 2007 Aug-Sep;28(2-3):97-114
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase.
  • Hypophysiotropic thyrotropin-releasing hormone (TRH): synthesizing neurons reside in the hypothalamic paraventricular nucleus (PVN) and are the central regulators of the hypothalamic-pituitary-thyroid (HPT) axis.
  • TRH synthesis and release from these neurons are primarily under negative feedback regulation by thyroid hormone.
  • Under certain conditions such as cold exposure and fasting, however, inputs from neurons in the brainstem and hypothalamic arcuate and dorsomedial nuclei alter the set point for negative feedback through regulation of CREB phosphorylation.
  • Thus, during cold exposure, adrenergic neurons stimulate the HPT axis, while fasting-induced central hypothyroidism is mediated through an arcuato-paraventricular pathway.
  • Feedback regulation of TRH neurons may also be modified by local tissue levels of thyroid hormone regulated by the activation of type 2 iodothyronine deiodinase (D2), the primary enzyme in the brain that catalyzes T4 to T3 conversion.
  • During infection, endotoxin or endotoxin induced cytokines increase D2 activity in the mediobasal hypothalamus, which by inducing local hyperthyroidism, may play an important role in infection-induced inhibition of hypophysiotropic TRH neurons.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10862-7 [9380725.001]
  • [Cites] Diabetes. 1997 Dec;46(12):2119-23 [9392508.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4032-6 [9398708.001]
  • [Cites] Brain Res. 2002 Dec 13;957(2):251-8 [12445967.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4513-9 [12446577.001]
  • [Cites] Endocrinology. 2003 Jan;144(1):281-91 [12488356.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1331-40 [12639916.001]
  • [Cites] Brain Res. 2003 Jun 20;976(1):130-4 [12763631.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E470-80 [12736158.001]
  • [Cites] J Neurosci. 2003 Nov 19;23(33):10691-702 [14627654.001]
  • [Cites] Brain Behav Immun. 2004 Mar;18(2):123-34 [14759590.001]
  • [Cites] Brain Res. 2004 Mar 5;999(2):181-92 [14759497.001]
  • [Cites] Brain Res. 2004 Mar 26;1002(1-2):43-50 [14988032.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):1649-55 [14684601.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):1695-9 [14691017.001]
  • [Cites] Brain Res. 2004 Apr 23;1006(1):1-7 [15047018.001]
  • [Cites] Endocrinology. 2004 May;145(5):2221-7 [14764630.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3619-25 [15087435.001]
  • [Cites] J Endocrinol. 2004 Aug;182(2):315-23 [15283692.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4737-47 [15231696.001]
  • [Cites] J Endocrinol Invest. 2004;27(6 Suppl):105-19 [15481810.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):4816-21 [15256492.001]
  • [Cites] Endocrinology. 1965 Nov;77(5):797-801 [4284776.001]
  • [Cites] Biochem Biophys Res Commun. 1966 Oct 20;25(2):165-9 [5971762.001]
  • [Cites] Endocrinology. 1974 Nov;95(5):1398-410 [4426296.001]
  • [Cites] Can J Neurol Sci. 1974 Feb;1(1):59-73 [4140015.001]
  • [Cites] Cell Tissue Res. 1977 May 16;180(2):263-82 [194701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Dec;75(12):6300-4 [366617.001]
  • [Cites] Cell Tissue Res. 1979 Oct;201(3):377-408 [389426.001]
  • [Cites] J Comp Neurol. 1980 Dec 1;194(3):555-70 [7451682.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1432-8 [11245447.001]
  • [Cites] J Clin Invest. 2001 Apr;107(8):1017-23 [11306605.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2606-13 [11356711.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Jun 20;90(2):93-100 [11406287.001]
  • [Cites] Neuroreport. 2001 Jul 3;12(9):1793-7 [11435900.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1379-85 [11696583.001]
  • [Cites] Neuroendocrinology. 2001 Dec;74(6):407-22 [11752897.001]
  • [Cites] J Endocrinol Invest. 2001 Dec;24(11):897-913 [11817716.001]
  • [Cites] Endocr Rev. 2002 Feb;23(1):38-89 [11844744.001]
  • [Cites] J Endocrinol Invest. 2002 Mar;25(3):268-88 [11936472.001]
  • [Cites] Neurosci Lett. 2002 May 10;324(1):69-73 [11983297.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):73-9 [11988078.001]
  • [Cites] Endocrinology. 1982 Feb;110(2):367-75 [6276132.001]
  • [Cites] Endocrinology. 1982 Jul;111(1):55-65 [6806077.001]
  • [Cites] Nature. 1982 Aug 12;298(5875):686-8 [7099265.001]
  • [Cites] Acta Endocrinol (Copenh). 1983 Mar;102(3):377-85 [6681926.001]
  • [Cites] Acta Physiol Scand. 1983 Jul;118(3):293-5 [6312755.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Dec 30;141(3):1201-6 [3545198.001]
  • [Cites] Annu Rev Physiol. 1987;49:321-34 [3551803.001]
  • [Cites] J Comp Neurol. 1987 Apr 8;258(2):204-29 [3294923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3628-32 [3473473.001]
  • [Cites] Science. 1987 Oct 2;238(4823):78-80 [3116669.001]
  • [Cites] Brain Res. 1987 Sep 8;420(1):194-8 [3676753.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1357-63 [15604205.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1701-6 [15661862.001]
  • [Cites] Brain Res. 2005 Mar 28;1039(1-2):53-62 [15781046.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2827-33 [15746256.001]
  • [Cites] Endocrinology. 2005 Jul;146(7):2985-91 [15831569.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4322-34 [15840737.001]
  • [Cites] Thyroid. 2005 Aug;15(8):757-68 [16131319.001]
  • [Cites] Thyroid. 2005 Aug;15(8):883-97 [16131331.001]
  • [Cites] Brain Res. 2005 Dec 7;1064(1-2):42-51 [16336950.001]
  • [Cites] Int Rev Cytol. 2005;247:89-164 [16344112.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):520-9 [16210367.001]
  • [Cites] Endocrinology. 2006 May;147(5):2591-6 [16484326.001]
  • [Cites] Endocrinology. 2006 Jun;147(6):2705-16 [16497799.001]
  • [Cites] Endocrinology. 2006 Jul;147(7):3296-306 [16627588.001]
  • [Cites] Prog Brain Res. 2006;153:209-35 [16876577.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4036-43 [16709608.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4419-29 [16728495.001]
  • [Cites] Cell Metab. 2007 Jan;5(1):21-33 [17189204.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):627-35 [17318265.001]
  • [Cites] Peptides. 1992 Jul-Aug;13(4):677-80 [1359508.001]
  • [Cites] Brain Res Bull. 1993;30(5-6):611-6 [8457909.001]
  • [Cites] J Chem Neuroanat. 1997 Oct;13(4):265-79 [9412908.001]
  • [Cites] Brain Res. 1997 Nov 28;777(1-2):231-6 [9449434.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):741-6 [9435263.001]
  • [Cites] Diabetes. 1998 Feb;47(2):294-7 [9519731.001]
  • [Cites] Neuroimmunomodulation. 1997 Jul-Aug;4(4):188-94 [9524963.001]
  • [Cites] Horm Res. 1998;49(3-4):173-7 [9550121.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):2879-84 [9607797.001]
  • [Cites] Endocrinology. 1998 Jul;139(7):3262-70 [9645702.001]
  • [Cites] Neuroendocrinology. 1998 Aug;68(2):89-97 [9705575.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Feb 29;151(1):615-22 [3126740.001]
  • [Cites] Endocrinology. 1988 Jul;123(1):567-71 [3133201.001]
  • [Cites] Neuroendocrinology. 1988 May;47(5):384-8 [3135505.001]
  • [Cites] Endocrinology. 1988 Nov;123(5):2291-7 [3139393.001]
  • [Cites] Ann N Y Acad Sci. 1989;553:191-6 [2497671.001]
  • [Cites] Ann N Y Acad Sci. 1989;553:205-13 [2497672.001]
  • [Cites] Ann N Y Acad Sci. 1989;553:29-59 [2497675.001]
  • [Cites] Neurosci Lett. 1989 May 22;100(1-3):169-74 [2548126.001]
  • [Cites] Endocrinology. 1990 May;126(5):2444-53 [2109687.001]
  • [Cites] Horm Metab Res Suppl. 1990;23:12-7 [2210627.001]
  • [Cites] Endocrinology. 1990 Dec;127(6):2955-62 [2123445.001]
  • [Cites] Histochemistry. 1987;88(1):1-10 [2893779.001]
  • [Cites] Brain Res. 2002 Jul 26;945(1):50-9 [12113951.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):413-21 [12220554.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):3846-53 [12239096.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2283-96 [12351693.001]
  • [Cites] Neuroendocrinology. 1991 Nov;54(5):477-81 [1749462.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):725-34 [12360211.001]
  • [Cites] Endocrinology. 1992 Jan;130(1):364-72 [1727710.001]
  • [Cites] Endocrinology. 1992 May;130(5):2845-50 [1572297.001]
  • [Cites] Endocrinology. 1992 Jun;130(6):3608-16 [1597158.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] Ciba Found Symp. 1992;168:144-58; discussion 158-64 [1425022.001]
  • [Cites] Neuroendocrinology. 1992 Sep;56(3):348-53 [1436373.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):151-64 [9920076.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):814-7 [9927310.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 2):R864-71 [10070149.001]
  • [Cites] Nat Neurosci. 1998 Aug;1(4):271-2 [10195157.001]
  • [Cites] Neurosci Lett. 1999 Apr 2;264(1-3):113-6 [10320027.001]
  • [Cites] Endocrinology. 1999 Aug;140(8):3643-52 [10433222.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):291-300 [10430610.001]
  • [Cites] Neuroscience. 1999;93(4):1449-64 [10501470.001]
  • [Cites] Endocr Rev. 1999 Oct;20(5):599-648 [10529897.001]
  • [Cites] Brain Res. 2005 Jan 25;1032(1-2):171-5 [15680956.001]
  • [Cites] Neuroendocrinology. 1990 Nov;52(5):422-8 [1704108.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2116-26 [8404661.001]
  • [Cites] Neuroendocrinology. 1993 Jul;58(1):140-5 [8264848.001]
  • [Cites] Endocrinology. 1994 Jul;135(1):92-100 [7516871.001]
  • [Cites] Brain Res Bull. 1995;36(4):381-92 [7712198.001]
  • [Cites] Acta Biol Hung. 1994;45(2-4):361-74 [7725828.001]
  • [Cites] J Endocrinol. 1995 Apr;145(1):143-53 [7798020.001]
  • [Cites] Science. 1995 Jul 28;269(5223):543-6 [7624777.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3346-52 [7628370.001]
  • [Cites] Mol Endocrinol. 1995 May;9(5):540-50 [7565802.001]
  • [Cites] Neuroscience. 1995 Dec;69(3):711-26 [8596642.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):3006-15 [8670802.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):95-7 [8782827.001]
  • [Cites] J Clin Invest. 1996 Sep 1;98(5):1101-6 [8787671.001]
  • [Cites] Neuroendocrinology. 1996 Oct;64(4):257-67 [8895854.001]
  • [Cites] Nature. 1997 Jan 9;385(6612):165-8 [8990120.001]
  • [Cites] Endocrinology. 1997 Jun;138(6):2569-76 [9165050.001]
  • [Cites] Brain Res. 1997 May 30;758(1-2):259-62 [9203559.001]
  • [Cites] Endocrinology. 1997 Aug;138(8):3359-68 [9231788.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):3624-9 [9275045.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10391-6 [9294221.001]
  • [Cites] J Neurocytol. 1997 Jul;26(7):479-90 [9306246.001]
  • [Cites] Science. 1997 Oct 3;278(5335):135-8 [9311920.001]
  • [Cites] Brain Res. 1998 Aug 17;802(1-2):141-54 [9748546.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4428-31 [9751529.001]
  • [Cites] J Neuroendocrinol. 1998 Oct;10(10):731-42 [9792325.001]
  • [Cites] Thyroid. 1998 Oct;8(10):887-94 [9827655.001]
  • [Cites] Neuron. 1998 Dec;21(6):1375-85 [9883730.001]
  • [Cites] J Neurosci. 2000 Feb 15;20(4):1550-8 [10662844.001]
  • [Cites] J Clin Invest. 2000 Apr;105(7):1005-11 [10749579.001]
  • [Cites] J Pept Sci. 2000 Mar;6(3):97-122 [10759209.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):661-71 [10766253.001]
  • [Cites] Brain Res. 2000 Apr 17;862(1-2):154-61 [10799680.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2596-603 [10902813.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3832-41 [11014240.001]
  • [Cites] Physiol Rev. 2000 Oct;80(4):1523-631 [11015620.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36124-33 [10967095.001]
  • [Cites] J Endocrinol. 2000 Dec;167(3):505-15 [11115778.001]
  • [Cites] J Neurosci. 2000 Dec 15;20(24):9224-34 [11125000.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):111-20 [11134186.001]
  • [Cites] Brain Res. 2001 Feb 9;891(1-2):20-31 [11164806.001]
  • (PMID = 17588648.001).
  • [ISSN] 0091-3022
  • [Journal-full-title] Frontiers in neuroendocrinology
  • [ISO-abbreviation] Front Neuroendocrinol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-37021; United States / NIDDK NIH HHS / DK / R01 DK037021; United States / NIDDK NIH HHS / DK / R01 DK037021-21; United States / NIDDK NIH HHS / DK / DK037021-21; United States / NIDDK NIH HHS / DK / R56 DK037021
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5Y5F15120W / Thyrotropin-Releasing Hormone; EC 1.11.1.- / iodothyronine deiodinase type II; EC 1.11.1.8 / Iodide Peroxidase
  • [Number-of-references] 160
  • [Other-IDs] NLM/ NIHMS27944; NLM/ PMC2000455
  •  go-up   go-down


40. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, Knüchel R, Klopocki E, Sauter G, Simon R, Wieland WF, Walter B, Denzinger S, Hartmann A, Hammerschmied CG: Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene; 2007 Aug 16;26(38):5680-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
  • Oncogenic wingless-related mouse mammary tumour virus (Wnt) signalling, caused by epigenetic inactivation of specific pathway regulators like the putative tumour suppressor secreted frizzled-related protein 1 (SFRP1), may be causally involved in the carcinogenesis of many human solid tumours including breast, colon and kidney cancer.
  • This TMA contained 132 different tumour subtypes as well as 26 different normal tissues.
  • Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours.
  • We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis.
  • Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours.
  • Our results indicate that loss of SFRP1 expression is a very common event in human cancer, arguing for a fundamental role of aberrant Wnt signalling in the development of solid tumours.
  • In RCC, promoter hypermethylation seems to be the predominant mechanism of SFRP1 gene silencing and may contribute to initiation and progression of this disease.
  • [MeSH-major] Gene Expression Profiling. Intercellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA Methylation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Loss of Heterozygosity. Middle Aged. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353908.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SFRP1 protein, human
  •  go-up   go-down


41. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood and Marrow Transplant Clinical Trials Network: Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood; 2009 Jul 16;114(3):511-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
  • Acute graft-versus-host disease (aGVHD) is the primary limitation of allogeneic hematopoietic cell transplantation.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Graft vs Host Disease / prevention & control. Mycophenolic Acid / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antineoplastic Agents. Child. Diphtheria Toxin / therapeutic use. Drug Therapy, Combination. Etanercept. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Humans. Immunoglobulin G / therapeutic use. Infection / chemically induced. Interleukin-2 / therapeutic use. Methylprednisolone / administration & dosage. Middle Aged. Pentostatin / therapeutic use. Receptors, Tumor Necrosis Factor / therapeutic use. Recombinant Fusion Proteins / therapeutic use. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2000;6(4A):441-7 [10975513.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(7):387-94 [12171485.001]
  • [Cites] Eur J Haematol. 2004 Jul;73(1):56-61 [15182339.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1224-6 [15113758.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1559-64 [15138163.001]
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Blood. 1990 Feb 15;75(4):1024-30 [2302454.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1821-8 [2015405.001]
  • [Cites] Transplantation. 1991 Jun;51(6):1197-203 [2048196.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1225-30 [8413388.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):437-42 [8073512.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Blood. 1996 Aug 1;88(3):824-30 [8704237.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(1):61-5 [9678797.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2288-93 [9746766.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2303-14 [9746768.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Mar;11(3):188-93 [15744237.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2661-8 [15837980.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2470-5 [18042798.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2888-94 [19001082.001]
  • (PMID = 19443659.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00224874
  • [Grant] United States / NHLBI NIH HHS / HL / U10 HL069294; United States / NHLBI NIH HHS / HL / U10 HL069290; United States / NCI NIH HHS / CA / U24 CA076518; United States / NHLBI NIH HHS / HL / U10 HL069286; United States / NHLBI NIH HHS / HL / U10 HL069301; United States / NHLBI NIH HHS / HL / U10 HL069330; United States / NHLBI NIH HHS / HL / U10 HL069249; United States / NHLBI NIH HHS / HL / U10 HL069348
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Immunoglobulin G; 0 / Interleukin-2; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 395575MZO7 / Pentostatin; HU9DX48N0T / Mycophenolic Acid; OP401G7OJC / Etanercept; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2713466
  •  go-up   go-down


42. Morio A, Ninomiya H, Sunada K, Tomioka K, Nakahara K: [A case of advanced non-small-cell lung cancer successfully treated with S-1 plus CBDCA after multiple chemotherapy]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced non-small-cell lung cancer successfully treated with S-1 plus CBDCA after multiple chemotherapy].
  • A 51-year-old man consulted our hospital with complaints of a headache and spasm of the left upper limbs in January 2007.
  • After the brain tumor extraction, CDDP (80 mg/m2) + GEM (1,000 mg/m2) were administered as first-line treatment, and the tumor response was PR (33.3% reduction rate), impaired liver function served to interrupt this regimen.
  • Other chemotherapy was then conducted in the order of GEM (1,000 mg/m2) + VNR (25 mg/m2), and CBDCA (AUC=5) + DOC(60 mg/m2), and the tumor response was NC.
  • After 3 courses of the treatment, the serum CEA level normalized, a chest CT detected the left lung tumor size reduction (66.7% reduction rate), and an abdominal CT detected disappearance of the left adrenal gland tumor.
  • Histopathological examination of the lung tumor showed viable adenocarcinoma cells.
  • This case suggests that S-1+CBDCA may be an effective treatment in patients with advanced non-small-cell lung cancer even after multiple chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755827.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; BG3F62OND5 / Carboplatin
  •  go-up   go-down


43. Tanaka K, Yamada K, Sasaki H, Kishi K, Noura S, Takachi K, Eguchi H, Miyashiro I, Ohue M, Ohigashi H, Yano M, Ishikawa O, Imaoka S: [A surgical case of solitary lymph node metastatic recurrence of hepatocellular carcinoma after hepatectomy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1938-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No evidence of recurrence in the intra- and extra hepatic organs such as adrenal gland, lung, bone, and brain except for intra abdominal solitary lymph node metastasis was observed.
  • This patient currently survives without the disease for 30 months after the initial operation, and for 19 months after a resection of the meatastatic lymph node.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymphatic Metastasis / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212152.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


44. Miyazawa K, Kakazu N, Ohyashiki K: Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. Int J Hematol; 2007 Jan;85(1):5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Hypereosinophilic Syndrome / genetics. Hypereosinophilic Syndrome / pathology. Myeloproliferative Disorders / genetics. Oncogene Proteins, Fusion / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. mRNA Cleavage and Polyadenylation Factors / genetics

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7830-5 [12808148.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):412-6 [12800153.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1577-8 [12047970.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Int J Hematol. 2006 Apr;83(3):243-6 [16720555.001]
  • [Cites] Ann Hematol. 2006 Jan;85(1):1-16 [16136348.001]
  • [Cites] Blood. 2003 May 1;101(9):3391-7 [12506022.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2802-5 [14630792.001]
  • [Cites] Int J Hematol. 2005 May;81(4):310-4 [15914361.001]
  • [Cites] Blood. 2004 Jan 15;103(2):473-8 [14504092.001]
  • [Cites] Blood. 2004 Nov 15;104(10 ):3038-45 [15284118.001]
  • [Cites] Am J Cardiol. 2000 Jul 1;86(1):110-3 [10867107.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2879-91 [15070659.001]
  • [Cites] Blood. 2003 Jun 15;101(12 ):4660-6 [12676775.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S79-80 [15036947.001]
  • [Cites] Medicine (Baltimore). 1975 Jan;54(1):1-27 [1090795.001]
  • [Cites] Leukemia. 2005 May;19(5):792-8 [15772698.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3093-6 [12842979.001]
  • [Cites] Ann Intern Med. 1968 Jun;68(6):1220-9 [5653621.001]
  • (PMID = 17261495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / FIP1L1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / mRNA Cleavage and Polyadenylation Factors; 9PHQ9Y1OLM / Prednisolone; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


45. Lumb A, Wass J: Expanding boundaries of endocrinology. Clin Med (Lond); 2010 Jun;10(3):238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specialist transethmoidal endoscopic surgery has improved results in pituitary tumour patients and minimally invasive parathyroid surgery has had the same consequence in patients with parathyroid disease.
  • Multidisciplinary teams have improved outcomes in a number of areas and, as described above, endocrinologists are dealing with more in the way of endocrine disease to expand boundaries.
  • Much work remains to be done particularly concerning the care of children and adults with late endocrine effects of cancer treatment and obesity.
  • [MeSH-minor] Adrenal Gland Neoplasms / complications. Adult. Diphosphonates / therapeutic use. Female. Humans. Hyperparathyroidism / surgery. Hypertension / etiology. Neoplasms / epidemiology. Obesity / epidemiology. Osteoporosis / drug therapy. Osteoporosis / epidemiology. Pheochromocytoma / complications. Polycystic Ovary Syndrome / epidemiology. Prolactinoma / epidemiology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726452.001).
  • [ISSN] 1470-2118
  • [Journal-full-title] Clinical medicine (London, England)
  • [ISO-abbreviation] Clin Med (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


46. Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH, Kebebew E: Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg; 2008 May;32(5):873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.
  • As genes on this chromosome may be important in the pathogenesis of adrenocortical carcinoma, we compared their expression profile between benign and malignant adrenocortical tissue.
  • The area under the receiver operating characteristic (ROC) curve (AUC) was used to determined the diagnostic accuracy of the differently expressed genes for distinguishing benign from malignant tumors.
  • RESULTS: We found 25 of the 314 genes on chromosome 11q13 to be differentially expressed between adrenocortical carcinoma and benign adrenocortical tumor.
  • Six genes (SERPING1, MRPL48, TM7SF2, DDB1, NDUSF8, PRDX5) validated by RT-PCR were significantly differentially expressed between benign and malignant adrenocortical tumors (p<0.05) with an overall accuracy of 89% for SERPING1, 91% for MRPL48, 87% for TM7SF2, 88% for DDB1, 91% for NDUFS8, and 89% for PRDX5.
  • CONCLUSIONS: We have identified 25 genes located on chromosome 11q13 that are downregulated in adrenocortical carcinoma and may be candidate tumor suppressor genes.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Chromosomes, Human, Pair 11 / genetics. Genes, Tumor Suppressor / physiology. Loss of Heterozygosity / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2733-7 [17301228.001]
  • [Cites] Neurology. 2004 May 25;62(10):1899-901 [15159508.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Pathology. 2007 Jun;39(3):299-304 [17558856.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4097-106 [15930345.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):76-81 [1352309.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):212-7 [11668500.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22865-74 [16760464.001]
  • [Cites] J Chir (Paris). 1989 Jun-Jul;126(6-7):385-7 [2570788.001]
  • [Cites] FEBS J. 2006 Jun;273(12):2607-17 [16817890.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2268-73 [17557902.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Clin Immunol. 2005 Jan;114(1):3-9 [15596403.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):730-5 [10022445.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Eur J Cancer. 1992;28A(8-9):1441-6 [1515267.001]
  • [Cites] Intern Med. 2006;45(20):1107-11 [17106152.001]
  • [Cites] Biochim Biophys Acta. 2006 Jul;1761(7):677-85 [16784888.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):13-8 [14685087.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):441-8 [10634422.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):164-74 [11955626.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5329-33 [11034065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12 ):6870-5 [9618505.001]
  • [Cites] OMICS. 2002;6(3):273-9 [12427278.001]
  • [Cites] J Urol. 2007 Mar;177(3):822-31 [17296351.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9419-26 [15543234.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):216-9 [9920087.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • (PMID = 18324346.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


47. Hankinson SE, Eliassen AH: Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer; 2010 Feb;1(1):2-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating sex steroids and breast cancer risk in premenopausal women.
  • Evidence from both laboratory and epidemiologic studies indicate a key role of hormones in the etiology of breast cancer.
  • In epidemiologic studies, indirect data, including the consistent associations observed between reproductive factors and breast cancer risk, support an important contribution of hormones to risk.
  • Recently, the associations between circulating hormones in premenopausal women and subsequent risk of breast cancer have been evaluated.
  • To date, both positive and null associations have been observed for estrogens and inverse and null associations for progesterone with breast cancer risk.
  • Few studies have evaluated estrogen metabolites in relation to breast cancer risk; hence, no conclusions can yet be drawn.
  • Findings for the largely adrenal-derived dehydroepiandrosterone (DHEA) and DHEA sulfate also are inconsistent and may vary by age.
  • However, relatively consistent positive associations have been observed between testosterone (or free testosterone) levels and breast cancer risk; these associations are of similar magnitude to those confirmed among postmenopausal women.
  • In this review, we summarize current evidence and identify gaps and inconsistencies that need to be addressed in future studies of sex steroids and premenopausal breast cancer risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):7831-5 [3186693.001]
  • [Cites] Mol Cell Endocrinol. 1989 Feb;61(2):239-46 [2537243.001]
  • [Cites] J Steroid Biochem. 1989 Apr;32(4):485-92 [2542691.001]
  • [Cites] J Steroid Biochem. 1989 Sep;33(3):417-21 [2779234.001]
  • [Cites] J Clin Epidemiol. 1991;44(10):1055-61 [1940998.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):1-4 [1530765.001]
  • [Cites] Steroids. 1991 Jul;56(7):361-6 [1780952.001]
  • [Cites] Am J Epidemiol. 1992 Dec 1;136(11):1400-13 [1488967.001]
  • [Cites] Epidemiol Rev. 1993;15(1):17-35 [8405201.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):477-86 [14623547.001]
  • [Cites] Breast Cancer Res Treat. 1993;27(1-2):3-15 [8260728.001]
  • [Cites] Lancet. 1994 Jun 11;343(8911):1479-81 [7911183.001]
  • [Cites] Cancer Detect Prev. 1994;18(2):79-85 [8025899.001]
  • [Cites] Am J Epidemiol. 1994 Sep 15;140(6):518-25 [8067345.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Chem Res Toxicol. 1996 Jul-Aug;9(5):851-9 [8828920.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):917-22 [8922301.001]
  • [Cites] Breast Cancer Res Treat. 1997 Feb;42(3):215-26 [9065605.001]
  • [Cites] Steroids. 1997 Mar;62(3):268-303 [9071738.001]
  • [Cites] Br J Cancer. 1997;75(7):1075-9 [9083346.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42 [9380738.001]
  • [Cites] Breast Cancer Res Treat. 1998;49 Suppl 1:S1-7; discussion S33-7 [9797011.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1250-5 [9820189.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):413-9 [10030690.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65 [15601642.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):755-65 [15900045.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108 [15908197.001]
  • [Cites] Anal Chem. 2005 Oct 15;77(20):6646-54 [16223252.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Dec;97(5):451-8 [16230007.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):270-82 [16421368.001]
  • [Cites] Maturitas. 2006 Apr 20;54(1):72-7 [16213115.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):967-71 [16702378.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15 [17018787.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):940-9 [17913663.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3411-8 [19064556.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3235-58 [19470930.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2273-9 [19661086.001]
  • [Cites] J Steroid Biochem Mol Biol. 2009 Oct;117(1-3):31-41 [19591931.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1059-64 [10613337.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):575-9 [10868691.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):135-45 [10963625.001]
  • [Cites] Epidemiology. 2000 Nov;11(6):635-40 [11055622.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):489-97 [11238191.001]
  • [Cites] Dis Markers. 2000;16(3-4):151-7 [11381198.001]
  • [Cites] Chem Res Toxicol. 2001 Aug;14(8):1041-50 [11511178.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7945-53 [11753677.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):175-89 [11897502.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Maturitas. 2002 Sep 30;43(1):1-10 [12270576.001]
  • [Cites] Breast Cancer Res. 2002;4(6):240-3 [12473170.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):296-300 [12559863.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):179-86 [12790780.001]
  • [Cites] JAMA. 2003 Jun 25;289(24):3243-53 [12824205.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):153-9 [14710223.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31 [15181033.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2763-9 [15181055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1032-6 [15184260.001]
  • [Cites] Breast Cancer Res. 2004;6(5):213-8 [15318928.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):312-8 [15352045.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1490-500 [15378477.001]
  • [Cites] Fertil Steril. 2004 Oct;82 Suppl 3:1160-70 [15474090.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2860-8 [19843676.001]
  • [Cites] J Endocrinol. 1981;89 Suppl:119P-129P [6453915.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(10):3320-4 [6808508.001]
  • [Cites] Endocrinology. 1983 Feb;112(2):486-91 [6848360.001]
  • [Cites] Steroids. 1983 May;41(5):643-56 [6658896.001]
  • [Cites] J Biol Chem. 1984 Apr 25;259(8):4840-5 [6325410.001]
  • [Cites] Am J Epidemiol. 1987 May;125(5):791-9 [3565354.001]
  • [Cites] Horm Res. 1987;28(2-4):212-8 [3331374.001]
  • (PMID = 21761346.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067262; United States / NCI NIH HHS / CA / R01 CA067262-10; United States / NCI NIH HHS / CA / R01 CA67262
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Other-IDs] NLM/ NIHMS335122; NLM/ PMC3253362
  •  go-up   go-down


48. Menzel T, Peters K, Hammerschmidt S, Ritter O: Metastatic signet ring cell gastric carcinoma presenting as an infrarenal aortic aneurysm. Gastric Cancer; 2005;8(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases to liver, lungs, bone, and adrenal glands are common events in advanced gastric carcinoma.
  • Occasionally, metastases to other parts of the body, such as the prostate gland [1] the gluteal muscle [2], or the cervix [3] are described.
  • However, these are rare events in the natural history of the disease.
  • We report an unusual case of a signet ring cell gastric carcinoma, initially presenting as an infrarenal aortic aneurysm.
  • The primary tumor, a signet ring cell gastric carcinoma, was detected by a subsequent esophago-gastro-duodenoscopy.
  • [MeSH-major] Aortic Aneurysm / etiology. Carcinoma, Signet Ring Cell / complications. Carcinoma, Signet Ring Cell / pathology. Lymphatic Metastasis. Stomach Neoplasms / complications. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747175.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Shueng PW, Lin SC, Chang HT, Chong NS, Chen YJ, Wang LY, Hsieh YP, Hsieh CH: Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol; 2009;4:71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report a case of a pathologic compression fracture of the T9 vertebra in a 55-year-old patient with cholangiocarcinoma.
  • [MeSH-major] Radiation Pneumonitis / etiology. Radiotherapy, Intensity-Modulated / adverse effects. Spinal Neoplasms / radiotherapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antioxidants / therapeutic use. Bile Duct Neoplasms / secondary. Bile Ducts, Intrahepatic / pathology. Cervical Vertebrae / injuries. Cholangiocarcinoma / pathology. Combined Modality Therapy. Humans. Middle Aged. Spinal Fractures / etiology. Spine. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2009 Feb;8(1):29-38 [19166240.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1517-24 [19084348.001]
  • [Cites] Nat Rev Cancer. 2009 May;9(5):351-60 [19377507.001]
  • [Cites] Radiat Oncol. 2008;3:36 [18976463.001]
  • [Cites] Radiat Oncol. 2008;3:33 [18831728.001]
  • [Cites] Radiat Oncol. 2008;3:21 [18662379.001]
  • [Cites] Radiat Oncol. 2008;3:11 [18426607.001]
  • [Cites] Radiat Oncol. 2007;2:21 [17553175.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4295-302 [17483342.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):215-7 [17406804.001]
  • [Cites] Radiat Oncol. 2006;1:31 [16939650.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):126-34 [16904518.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):915-21 [9531377.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):467-76 [9457837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):361-9 [7836090.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):985-97; discussion 998 [15256622.001]
  • [Cites] Cancer. 2004 May 1;100(9):1793-9 [15112258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):110-5 [12504042.001]
  • [Cites] Radiat Oncol. 2009;4:59 [19943923.001]
  • [Cites] Radiat Med. 1999 Nov-Dec;17(6):411-6 [10646976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):394-400 [12023144.001]
  • (PMID = 20043839.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antioxidants
  • [Other-IDs] NLM/ PMC2806297
  •  go-up   go-down


50. Higley EB, Newsted JL, Zhang X, Giesy JP, Hecker M: Assessment of chemical effects on aromatase activity using the H295R cell line. Environ Sci Pollut Res Int; 2010 Jun;17(5):1137-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECOMMENDATIONS AND PERSPECTIVES: For future work with the H295R, it is recommended that a combination of direct and indirect aromatase measurements is used because it was best in predicting the effects of a chemical on E2 production and its mechanism of action.
  • [MeSH-minor] Adrenal Cortex / enzymology. Adrenocortical Carcinoma / enzymology. Cell Line, Tumor. Ecotoxicology / methods. Enzyme-Linked Immunosorbent Assay. Estradiol / metabolism. Fungicides, Industrial / chemistry. Fungicides, Industrial / toxicity. Herbicides / chemistry. Herbicides / toxicity. Humans. Risk Assessment. Testosterone / metabolism. Time Factors